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DEVELOPMENT OF A METHOD FOR THE SCREENING OF SPORTS 
DOPING COMPOUNDS USING MULTIDIMENSIONAL LIQUID 
CHROMATOGRAPHY AND TIME OF FLIGHT MASS SPECTROMETRY 
 
ROBERT JAMES WALSH 
ABSTRACT 
 Athletes have often resorted to a variety of methods to gain an edge in sporting 
competitions. One such method is through doping, the use of compounds or methods to 
produce a theoretically enhancing biological effect. In order to combat doping, many 
governing sports bodies have prohibited specific compounds or methods and installed 
programs to test for these compounds in athletes. However, due to the large number of 
banned substances and the varying chemistries of those compounds, it can be challenging 
and time consuming to determine the presence of those compounds in an athlete’s 
sample. Therefore, there is a necessity to develop a quick and sensitive method that can 
precisely and accurately screen for banned substances. 
 This research was an attempt to develop such a method. This was accomplished 
using multidimensional liquid chromatography with time of flight mass spectrometry. 
While none of the methods tested here were useful for screening all 79 compounds tested 
in a single injection, a multi-method approach was evaluated in lieu of a multi-residues 
single method process The analytical run time was less than 10 minutes for each method. 
Further studies were performed to determine the limit of detection, linearity, lifetime, 
robustness and the optimal solid phase extraction method. 
vi 
 
TABLE OF CONTENTS 
Page 
Title Page                    i 
Reader’s Approval Page                iii 
Acknowledgements                 iv 
Abstract                   v 
Table of Contents                 vi 
List of Tables                  ix 
List of Figures                 xii 
List of Abbreviations               xiv 
1. Introduction                  1 
     1.1 Sports Doping                  1 
1.1.2 Anabolic Agents                2 
 1.1.3 Beta 2 Agonists                 3 
 1.1.4 Diuretics and Masking Agents               5 
 1.1.5 Stimulants                 6 
 1.1.6 Narcotics                 7 
 1.1.7 Beta Blockers                 8 
 1.1.8 Drugs of Abuse                 9 
    1.2 Testing for Doping                10 
 1.2.2 Current and Proposed Screening Methods                       12 
    1.3 Instrumentation Theory               13 
vii 
 
 1.3.1 Single Dimension Liquid Chromatography            14 
 1.3.2 Two Dimensional Liquid Chromatography            14 
 1.3.3 1D vs 2D Chromatography              16 
 1.3.4 Mass Spectrometry               16 
    1.4 Research Objective                18 
2. Materials and Methods                19 
    2.1 Materials                 19 
 2.1.1 Classes Optimized for Analysis              19 
 2.1.2 Anabolic Agents Evaluated              19 
 2.1.3 Beta 2 Agonists Evaluated              19 
 2.1.4 Diuretics and Masking Agents Evaluated            20 
 2.1.5 Stimulants Evaluated               20 
 2.1.6 Narcotics Evaluated               21 
 2.1.7 Beta Blockers Evaluated              22 
 2.1.8 Phenethylamines Evaluated              22 
 2.1.9 Benzodiazepines Evaluated              23 
 2.1.10 Piperazines Evaluated               23 
 2.1.11 Standards and Reagents              24 
 2.1.12 Instrumentation and Software              25 
    2.2 Methods                 26 
 2.2.1 Multiple Reaction Monitoring Optimization            26 
 2.2.2 Chromatography Method Development            34 
viii 
 
 2.2.3 Limit of Detection Determination                      38 
3 Results and Discussion                40 
    3.1 Anabolic Agents                40 
    3.2 Beta 2 Agonists                        40 
    3.3 Diuretics and Masking Agents                      41 
    3.4 Stimulants                         41 
    3.5 Narcotics                         42 
    3.6 Beta Blockers                         42 
    3.7 Phenethylamines                        43 
    3.8 Benzodiazepines                        43 
    3.9 Piperazines                                 44 
    3.10 Chromatography Combination                      44 
    3.11 Chromatography Results               45 
4 Conclusions                  53 
5 Future Considerations                55 
Appendices                       57 
List of Journal Abbreviations                94 
Bibliography                  95 
Curriculum Vitae               102  
   
ix 
 
LIST OF TABLES 
Page 
Table 1.  MRM Compound Optimization Table for Anabolic Agents          27 
Table 2.  MRM Compound Optimization Table for Beta 2 Agonists          28 
Table 3.  MRM Compound Optimization Table for Diuretics and Masking  
Agents                        28 
Table 4.  MRM Compound Optimization Table for Stimulants          29 
Table 5. MRM Compound Optimization Table for Narcotics           30 
Table 6. MRM Compound Optimization Table for Beta Blockers          31 
Table 7. MRM Compound Optimization Table for Phenethylamines          32 
Table 8. MRM Compound Optimization Table for Benzodiazepines          33 
Table 9. MRM Compound Optimization Table for Piperazines          34 
Table A. Details of 36 Chromatographic Methods Tested           57 
Table B. Chromatography Evaluation for Anabolic Agents. Methods 1-9          58 
Table C. Chromatography Evaluation for Anabolic Agents. Methods 10-18         59 
Table D. Chromatography Evaluation for Anabolic Agents. Methods 19-27         60 
Table E. Chromatography Evaluation for Anabolic Agents. Methods 28-36         61 
Table F. Chromatography Evaluation for Beta 2 Agonists. Methods 1-9         62 
Table G. Chromatography Evaluation for Beta 2 Agonists. Methods 10-18          63 
Table H. Chromatography Evaluation for Beta 2 Agonists. Methods 19-27         64 
Table I. Chromatography Evaluation for Beta 2 Agonists. Methods 28-36         65 
Table J.  Chromatography Evaluation for Diuretics and Masking Agents. 
x 
 
Methods 1-9                   66 
Table K. Chromatography Evaluation for Diuretics and Masking Agents  
Methods 10-18                67 
Table L.  Chromatography Evaluation for Diuretics and Masking Agents  
Methods 19-27                68 
Table M. Chromatography Evaluation for Diuretics and Masking Agents  
Methods 28-36                69 
Table N. Chromatography Evaluation for Stimulants. Methods 1-9          70 
Table O. Chromatography Evaluation for Stimulants. Methods 10-18          71 
Table P. Chromatography Evaluation for Stimulants. Methods 19-27          72 
Table Q. Chromatography Evaluation for Stimulants. Methods 28-36          73 
Table R. Chromatography Evaluation for Narcotics. Methods 1-9          74 
Table S. Chromatography Evaluation for Narcotics. Methods 10-18          75 
Table T. Chromatography Evaluation for Narcotics. Methods 19-27          76 
Table U. Chromatography Evaluation for Narcotics. Methods 28-36          77 
Table V. Chromatography Evaluation for Beta Blockers. Methods 1-9         78 
Table W. Chromatography Evaluation for Beta Blockers. Methods 10-18         79 
Table X. Chromatography Evaluation for Beta Blockers. Methods 19-27         80 
Table Y. Chromatography Evaluation for Beta Blockers. Methods 28-36         81 
Table Z. Chromatography Evaluation for Phenethylamines. Methods 1-9         82 
Table AA. Chromatography Evaluation for Phenethylamines. Methods 10-18         83 
Table AB. Chromatography Evaluation for Phenethylamines. Methods 18-27         84 
xi 
 
Table AC. Chromatography Evaluation for Phenethylamines. Methods 28-36         85 
Table AD. Chromatography Evaluation for Benzodiazepines. Methods 1-9         86 
Table AE. Chromatography Evaluation for Benzodiazepines. Methods 10-18         87 
Table AF. Chromatography Evaluation for Benzodiazepines. Methods 18-27         88 
Table AG. Chromatography Evaluation for Benzodiazepines. Methods 28-36         89 
Table AH. Chromatography Evaluation for Piperazines. Methods 1-9          90 
Table AI. Chromatography Evaluation for Piperazines. Methods 10-18         91 
Table AJ. Chromatography Evaluation for Piperazines. Methods 19-27         92 
Table AK. Chromatography Evaluation for Piperazines. Methods 27-36         93 
  
xii 
 
LIST OF FIGURES 
Page 
Figure 1. Structure of Anabolic Agents Analyzed            19 
Figure 2. Structure of Beta 2 Agonists Analyzed            20 
Figure 3. Structure of Diuretics and Masking Agents Analyzed          20 
Figure 4. Structure of Stimulants Analyzed             21 
Figure 5. Structure of Narcotics Analyzed             21 
Figure 6. Structure of Beta Blockers Analyzed             22 
Figure 7. Structures of Phenethylamines Analyzed            23 
Figure 8. Structures of Benzodiazepines Analyzed            23 
Figure 9. Structures of Piperazines Analyzed             24 
Figure 10. 6 X 6 Method Optimization Scheme             36 
Figure 11. Example of a Green Chromatogram              37 
Figure 12. Example of a Yellow Chromatogram             37 
Figure 13. Example of a Red Chromatogram             38 
Figure 14. TQS Chromatograms for 5 Phenethylamine Compounds.          47 
Figure 15.  TQS Chromatograms for 5 Remaining Phenethylamine Compounds       48 
Figure 16. Limit of Detection Chromatograms for 25D-NBOMe          49 
Figure 17. TOF MS Chromatograms for Phenethylamine Compounds,  
1 µg/mL                        50 
Figure 18. TOF MS Chromatograms for Phenethylamine Compounds,  
10 ng/mL                               51 
xiii 
 
Figure 19. TOF MS Chromatograms for Phenethylamine Compounds,  
1 ng/mL                        52 
  
xiv 
 
LIST OF ABBREVIATIONS 
1D  One Dimensional 
2D  Two Dimensional 
ACN  Acetonitrile 
β2  Beta 2 
BEH  Ethylene Bridged Hybrid 
BZP  1-Benzylpiperazine 
°C  Degrees Celsius 
CE  Capillary Electrophoresis 
CID  Collision Induced Dissociation 
CRC  Chromatographic Reference Compound 
Da  Daltons 
DBZP  1,4-Dibenzylpiperazine 
DCPP  2,3-Dichlorophenylpiperazine 
FA  Formic Acid 
g  Grams 
GABA  Gamma-Amino Butyric Acid 
GC  Gas Chromatography 
HLB  Hydro-Lipophilic Balance 
HPLC  High Performance Liquid Chromatography 
hr  Hour 
kV  Kilovolts 
xv 
 
L  Liters 
LC  Liquid Chromatography 
MA  Massachusetts 
MBZP  4-Methyl-1-benzylpiperazine 
mCPP  3-Chlorophenylpiperazine 
MDMA 3,4-methylenedioxymethamphetamine 
MDPV  Methylenedioxypyrovalerone 
MeOH  Methanol 
MeOPP 4-Methoxyphenylpiperazine 
MI  Michigan 
min  Minutes 
mg  Milligrams 
mL  Milliliters 
MO  Missouri 
MRM  Multiple Reaction Monitoring 
MS  Mass Spectrometry 
m/z  Mass to Charge Ratio 
ng  nanograms 
NH4OH Ammonium Hydroxide 
pCPP  4-Chlorophenylpiperazine 
PED  Performance Enhancing Drug 
pFPP  4-Fluorophenylpiperazine 
xvi 
 
pg  picograms 
RT  Retention Time 
RRT  Relative Retention Time 
S/N  Signal to Noise 
SPE  Solid Phase Extraction 
TFMPP 3-Trifluoromethylphenylpiperazine 
TOF  Time of Flight 
TQD  Triple Quadrupole 
TX  Texas  
µg  micrograms 
µL  microliter 
UPLC  Ultra Performance Liquid Chromatography 
WADA World Anti-Doping Agency
1 
 
1. INTRODUCTION 
1.1 Sports Doping 
In the hyper-competitive world of sports, athletes have often used any tactic they can 
to gain a real or perceived advantage over their opponents. This can include manipulating 
the loopholes in the rules of the sport, mentally attempting to get opponents to perform 
worse through trash talk, or tampering with the sports equipment. One such way that 
athletes can gain an advantage is through improving the performance or ability of their 
own bodies. This can be through legal methods, such as specialized diets and training 
regimens, or through the use of doping.1 
What constitutes doping can depend on the institution that governs a specific sport. 
Major League Baseball, the National Football League and the Fédération Internationale 
de Football Association each have their own policies regarding what doping is and how 
to test an athlete to determine if it has occurred.2–4 For the most worldwide view of what 
constitutes doping, the best resource is the World Anti-Doping Agency (WADA). 
Established in 1999 by the Lausanne Declaration on Doping in Sport, WADA was 
founded with the mandate to perform testing on athletes, as well as to coordinate the 
available research to promote preventive actions and determine standards for analyses 
and equipment.5 
WADA defines doping as “the occurrence of one or more anti-doping violations”.6 
This is expanded to mean that confirmation of doping by an athlete covers: the presence 
of prohibited substances or their metabolites whether in a provided sample or in their 
possession, the use of prohibited methods, refusing to provide a sample, or attempted 
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tampering with any part of the doping testing process.6 For WADA, three methods are 
prohibited: gene doping, manipulation of blood and chemical and physical manipulation.7 
WADA also prohibits the use of: over 150 specific compounds at all times, over 75 
specific compounds during a competition, 20 specific beta blockers during certain 
sporting competitions such as archery and golf, and alcohol during some sports such as 
archery and powerboating.7 Those compounds represent eleven different classes, of 
which six specific classes were chosen for inclusion in this study. A further three classes 
were evaluated, two containing derivatives of select prohibited compounds, and one 
containing drugs of abuse compounds. 
1.1.2 Anabolic Agents 
Anabolic agents are the first class of compounds whose use is prohibited by 
WADA. They are the most popular of the prohibited substances,  in 43% of all samples 
that tested positive for some doping.8 They are derivatives or metabolites of testosterone. 
The main function of testosterone in the body is synthesize new proteins in the cells of 
the body. The proteins produced depend on what type of cells are involved. It is through 
this function that testosterone has its main effects on the body, including the production 
of male characteristics. This can include deepening of the voice and increase in facial 
hair, particularly in women who use them. Whether used clinically or abused for 
performance enhancing effects, anabolic agents are taken to reproduce these effects.9,10  
There have been a variety of therapeutic uses for anabolic agents, both those that 
have since been replaced by other compounds and those that are still in use. These uses 
tend to be to replace or replicate testosterone that might not be present in a person’s body. 
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For example, diseases such as human immunodeficiency virus infections, cancer and 
liver failure can result in a decrease in testosterone, which anabolic agents can be used to 
help replace.10 Anabolic agents can also be used to help begin puberty in males and also 
to produce male characteristics for transgender men.11,12 Finally, some of the effects of 
anabolic agents are useful for males recovering from surgery.10  
It is the last of these effects that is most similar to the reason that anabolic agents 
are abused and why they are specifically abused for sports doping purposes. As 
mentioned above, the proteins produced by anabolic agents depend on the type of cell 
involved. In muscle cells, this protein synthesis results in the formation of new actin and 
myosin molecules, which are the molecules that form muscle tissue.10 While there is 
some debate as to their usefulness in this manner, anabolic agents are typically used to 
increase muscle mass and strength.9 This can be used for sports purposes to help increase 
the speed and strength of athletes, to better help athletes recover from injuries, and to 
help athletes recover more quickly from strenuous workouts.13,14 
When it comes to the purposes of prohibiting these substances, WADA makes a 
distinction between endogenous and exogenous anabolic agents. Exogenous anabolic 
agents are not in the body normally, and are often prohibited outright. An athlete is 
considered as violating the anti-doping code when these compounds are detected 
qualitatively. Endogenous anabolic agents are already present in the body, but they may 
be administered to increase their concentration. Their use is prohibited, but they must be 
measured quantitatively to determine if an athlete is violating the anti-doping code.7,15 
1.1.3 Beta 2 Agonists 
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Beta 2 (β2) agonists are named as such due to their mechanism of action. They are 
a class of compounds that bind to the β2 adrenergic receptor. When bound to this 
receptor, they produce an effect of relaxing the muscles in the lungs, which helps to 
improve the flow of air to the lungs. Clinically, they are primarily used to treat 
respiratory diseases, in particular chronic obstructive pulmonary disease and asthma.14,16 
These types of compounds have two reasons for abuse in sports, depending on the type of 
compound. The main reason is to improve endurance.17 Some β2 agonist compounds, 
including clenbuterol, are used for anabolic effects.14 When taken at higher than normal 
therapeutic doses, these agonists can help to reduce body fat and increase skeletal muscle 
mass. Clenbuterol specifically is used in conjunction with other anabolic steroids.18 
β2 agonists can be used to treat asthma, and as there are a significant number of 
athletes who have exercise induced asthma or another form of asthma, not all β2 agonists 
are prohibited in a qualitative matter.14,17,19 Inhaled salbutamol, formoterol and salmeterol 
are not prohibited below concentrations of 1600 micrograms (µg), 54 µg and 200 µg over 
24 hours, respectively.7 Furthermore, salbutamol and formoterol are not prohibited below 
concentrations of 1000 nanograms per milliliter (ng/mL) and 40 ng/mL in urine, 
respectively. Other β2 agonists are prohibited at any concentration if the athlete does not 
have a therapeutic use exemption, and clenbuterol, zeranol and zilpaterol are all 
prohibited as anabolic agents, despite being β2 agonists.7 
β2 agonists are not as commonly abused as other classes of prohibited substances. 
In 2016, they appeared in 172 WADA tested samples, accounting for 4% of samples in 
which a prohibited substance or method was detected.8  
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1.1.4 Diuretics and Masking Agents 
Diuretics are a class of compounds that are primarily clinically taken to increase 
the excretion of ions from the kidneys. Diuretics can be classified based on their chemical 
structure or on their method of action. Diuretics and masking agents comprise a fairly 
diverse group of doping agents. For example, loop diuretics decrease the reabsorption of 
sodium chloride by competing for the chloride site on the Na+-K+-2Cl- transporter and 
thiazides provide the same physiological effects, decreasing the reabsorption of sodium 
chloride, though they accomplish this effect by inhibiting the Na+/Cl- transporter.20,21 
Diuretics increase the amount of urine produced, and are often used by athletes in an 
attempt to decrease the concentration of other prohibited substances. This is done to 
avoid having prohibited substances detected during the analytical testing process.13,14 
However, this is not the only reason that diuretics can be taken by athletes. For sports that 
require weigh-ins, such as boxing and wrestling, athletes may take diuretics in an attempt 
to lose weight before their weigh-ins.14 Athletes from sports without weigh-ins have also 
been known to take diuretics for these effects. However, in these cases the athletes were 
attempting to lose weight to improve their appearance, as opposed to any sports-related 
purpose.22  
While diuretics make up the majority of this class of compounds, there are some 
compounds that are considered masking agents without having diuretic properties. For 
example, probenecid prevents the excretion of drugs, including anabolic agents.14 Thus, 
athletes who take probenecid will have a lower concentration of those drugs in their 
urine.14 Epitestosterone is listed as an anabolic agent on the WADA prohibited list, yet it 
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is often used for masking purposes. Labs often test the ratio of testosterone to 
epitestosterone in order to determine a doping event. In order to disguise an increase in 
testosterone, athletes take epitestosterone to ensure the ratio stays balanced to WADA 
approved levels.13,14 Probenecid is included in the diuretic and masking agents class of 
this study, and epitestosterone is included in the anabolic agent class in this study. 
Diuretics and masking agents were detected in 499 WADA tested samples.8 This 
accounted for 12% of all samples in which a WADA prohibited method or substance was 
detected.8 
1.1.5 Stimulants 
Stimulants mark the first of the WADA prohibited classes that are prohibited in 
competition only. The three main ways that stimulants produce their effects is through 
increase the release of neurotransmitters into the synaptic cleft, direct stimulation of 
postsynaptic receptors and inhibiting the reuptake of neurotransmitters. The method 
through which they do this depends on the stimulant in question.23 Stimulants have many 
physical effects on the body including elevation of heart rate and blood pressure.14 The 
main reason athletes take these compounds is for their psychological effects, as they 
improve mood and increase confidence, alertness, and energy.14 The WADA prohibited 
list divides them into specified and non-specified stimulants. Specified stimulants were 
chosen based on a variety of factors, including their health risk, potential for addiction, 
legitimate availability, and their pharmacology.14 There are 30 stimulants that are listed 
as “non-specified” with the remaining stimulants considered specified stimulants.7 There 
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is no difference in prohibition between specified and non-specified substances, with the 
difference between the two types of compounds coming from the sanctioning process. 
Stimulants were the third most detected class of compound in 2016.8 They were 
detected 568 times in WADA samples, which accounted for 13% of all samples with a 
positive result.8 
1.1.6 Narcotics 
Similar to stimulants, narcotics are a class of compounds that are only prohibited 
by WADA during competition. In the body, pain and nociception (the understanding of 
something negative happening to the body) are treated through the production of 
endorphins. These endorphins stimulate receptors and cause a sense of euphoria or well-
being, reducing the sensation of nociception. Narcotics generally act by stimulating the 
same receptors, and as a result they will often produce similar or magnified effects. They 
also work to inhibit the nerve impulses that transmit pain signals, and thus inhibit pain. 
Clinically, narcotics are often used for the treatment of pain, and athletes may use them 
out of competition to help recover from injuries sustained during competition.14 
There are no direct performance enhancing effects that result from taking 
narcotics. In fact, given the depressant and sleep-inducing effects that many of these 
compounds have, it may be more of a detriment to an athlete to take them. The main 
benefits that may cause an athlete to use narcotics is pain relief and euphoria inducing 
components. These two effects may allow an athlete to continue playing through an 
injury that would otherwise hamper them.14  
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Narcotics are among the least detected of all the sports doping compounds. They 
were detected in 49 WADA samples in 2016.8 This accounted for 1% of all of samples 
which tested positive for a WADA prohibited method or substance.8 
1.1.7 Beta Blockers 
Beta blockers are one of two classes of compounds that are unique on the WADA 
prohibited list in that they, along with alcohol, are only prohibited within certain sports. 
Beta blockers are specifically prohibited in archery, automobile racing, billiards, darts, 
golf, ski jumping, ski freestyle aerials, ski halfpipe, snowboard halfpipe, snowboard big 
air, and a variety of underwater sports.7 The reason for this is that beta blockers don’t 
have a performance enhancing effect for most sports. Beta blockers work by antagonizing 
beta receptors. Depending on the organ of the beta receptor and the type of beta receptor 
present, beta blockers can cause a variety of effects including increasing motility, 
constricting arteries and veins, and decreasing heart rate. Clinically, they are used to treat 
hypertension, heart failure, anxiety and tremors, among other uses.14 
It is this treatment of tremors for which athletes use beta blockers, as they allow 
athletes to keep a steady hand despite any anxiety that may occur due to the stress of 
competition. One of the most common adverse effects of beta blockers is fatigue. For 
athletes outside the sports listed above, this effect should deter any desire to use these 
compounds.14 Only in those sports, in which hand steadiness is tantamount to success, 
would this adverse effect not be detrimental enough to deter athletes from taking the 
compound. 
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As they are not prohibited in all sports, beta blockers are naturally detected less 
often than the other classes of compounds. As such, they were detected very rarely in 
2016. They were detected in only 14 cases, which was 0.3% of the samples that tested 
positively for a WADA prohibited substance.8 
1.1.8 Drugs of Abuse 
 While the main focus of this study is on compounds used in sports doping, there 
are three classes of compounds delineated in this study that are not specific groups to the 
WADA prohibited list, in the way that the other groups are. These three groups are three 
different classes of drugs of abuse: phenethylamines, benzodiazepines, and piperazines. 
While not specifically named, the WADA prohibited list includes the derivatives 
of phenethylamine, listed under the sections that outlines prohibited stimulants.7 It also 
includes one of the piperazines, benzylpiperazine (BZP) under the stimulant section as 
well. And while they are not specifically listed, it may be assumed that other piperazines 
compounds would be prohibited as “other substances with a similar chemical structure or 
similar biological effect(s).”7 Like other stimulants, the compounds of these two classes 
have effects such as raising blood pressure and heart rate, increasing friendliness and sex 
drive, and causing agitation and delirium.24,25 Furthermore, these compounds can cause 
hallucinogenic effects similar to drugs such as lysergic acid diethylamide or 3,4-
methylenedioxymethamphetamine (MDMA).26,27 Not much is known about how 
phenethylamine compounds produce these effects. However, since they are structurally 
similar to compounds such as methamphetamine, it is hypothesized that they act in a 
similar manner to those compounds. In fact, a study performed by Baumann et al. 
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concluded that one phenethylamine compound, methylenedioxypyrovalerone (MDPV), 
acts on similar transporters to those that cocaine and methamphetamine do, and in fact 
acts much more potently than cocaine.24 As for piperazines, studies have seen indications 
that BZP exerts its effect by inhibiting the reuptake of dopamine and norepinephrine in a 
manner similar to MDMA, though less potent.27  While the stimulant effects of these two 
classes of compounds might be useful in a sporting context, the hallucinogenic effects 
they are commonly abused for might prevent athletes from using them for a sporting 
purpose. 
Benzodiazepines, which are commonly abused prescription, are included in this 
study as they are Schedule IV on the Controlled Substances Act.28 They are depressant 
compounds that slow down the central nervous system and induce sleep.26 They are 
primarily prescribed as anxiolytics and muscle relaxants. Benzodiazepines work through 
interaction with the gamma-amino butyric acid (GABA) receptors. They bind to the 
GABAA receptor and decrease the amount of GABA needed to open the chloride ion 
channel. This increases the amount of chloride current generated by the GABAA receptor, 
which increases inhibition of neuronal activity.29 Differences in structure of 
benzodiazepines change the length of action, among other things. As they are muscle 
relaxants, benzodiazepines could possibly be taken by athletes for similar reasons to beta 
blockers. However, due to their sleep inducing activity, it seems unlikely that athletes 
would prefer to take them over beta blockers, except as a means of subverting WADA 
prohibitions. 
1.2 TESTING FOR DOPING 
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 As there are a variety of different methods and substances used for doping, there 
are a variety of testing methods that can be used to test for banned substances. For 
example, breath alcohol testing can be performed to test for the presence of alcohol, 
while a biomarkers test can be performed to detect human growth hormone.30,31 For many 
prohibited substances, testing is performed on a sample provided by the athlete and 
obtained by a trained and accredited Doping Control Officer or blood collection officer.32 
WADA guidelines indicate that the only biological matrices that should be collected for 
sports doping analysis are blood and urine, which each carry their own guidelines for 
collection.32–34 Depending on the performance enhancing drug (PED) and the testing 
being performed, sample pretreatment such as extraction or derivatization can be 
performed on the sample.  
After the sample pretreatment step, the main techniques performed by labs are 
gas-chromatography/mass spectrometry (GC/MS) or liquid-chromatography/mass 
spectrometry (LC/MS). WADA does not specify the analytical technique to be followed. 
However, they provide a series of minimum criteria for chromatography and mass 
spectrometry that labs must meet to properly identify an analyte.35 For chromatography, 
these criteria specify that the retention time (RT) of a questioned analyte cannot differ 
from the RT of a reference by more than 0.1 minutes or 1%, whichever is greater. Labs 
may also use the relative retention time (RRT) in relation to a chromatographic reference 
compounds (CRC). If the CRC is not the stable isotope-labeled analyte, the RRT of the 
analyte cannot differ from the RRT of the reference by more than 1% for an identification 
to be made. If the CRC is the stable isotope labeled analyte, the RRT of the questioned 
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analyte cannot differ from the RRT of the reference by more than 0.5% for an 
identification to be made. For MS, minimum criteria include that each mass used for 
identification be within 0.5 daltons (Da) of the same mass on the reference and that the 
signal to noise (S/N) ratio is greater than 3:1. There are also specifications that at least 
three diagnostic ions must be used for single stage MS, and that at least two diagnostic 
ions must be used for multiple stage MS. Also, the relative abundancies of ions must not 
differ from the reference spectra, though the tolerance for those differences depends on 
the relative abundance of the reference specimen. If those parameters cannot be met, then 
another ionization technique must be used before identification can be made.36 
1.2.2 Current and Proposed Screening Methods 
WADA provides no guidelines for what screening method to use, if any. WADA 
also provides no minimum criteria that a screening method must meet. The most useful 
screening methods are those that are relatively quick, those that can differentiate between 
the greatest number of analytes, and those that have the fewest number of false negatives 
and/or positives. In most labs that test for sports doping, chromatography and mass 
spectrometry are used for screening purposes as well as quantitation purposes.37 For 
screening applications, the sample preparation method used is a dilute-and-shoot.37,38 A 
dilute-and-shoot involves diluting the sample matrix, in this case urine, and injecting a 
portion of it directly into the system. For screening methods, this is useful in that it is fast, 
simple to perform and inexpensive.37 However, there are a variety of problems with 
dilute-and-shoot that make its use as a sample pretreatment technique ineffective. For 
example, there are a variety of matrix effects that have been observed with dilute and 
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shoot, including retention time shifts, ion suppression and enhancement, and interfering 
peaks.38,39 Also, clogging of the analytical column can occur when using dilute and 
shoot.38 Clogging of the column can shorten the lifetime of a column, leading to 
increased costs of the method. 
There have been other studies that have attempted to shorten the time of doping 
analysis, whether it be for screening purposes or otherwise. A variety of methods using 
capillary electrophoresis (CE) have been proposed. CE has been found to be useful in 
identifying diuretics and blood doping.15 However, the difficulty in coupling them with 
an MS system makes them less useful in detecting steroids.15 Another method was 
attempted using vacuum matrix-assisted laser desorption ionization coupled with linear 
ion trap MS. While this technique proved successful, it was a study on only 5 anabolic 
agent compounds, a small percentage of the over 200 compounds on the WADA 
prohibited list.40 Finally, a method similar to the one proposed here was proposed by 
Domínguez-Romero et al. in 2015.41 Like this method, it utilized a liquid 
chromatography system and time of flight mass spectrometry for screening of sports 
doping compounds.41 However, the method utilized a one dimensional (1D) high 
performance liquid chromatography (HPLC) system, while our proposed method uses a 
two dimensional (2D) ultra-performance liquid chromatography (UPLC) system. The 
extra dimension allows for a removal of the evaporation and reconstitution steps. 
Furthermore, the use of a UPLC system as opposed to an HPLC system allows for 
improved analytical run times with improved resolution.  
1.3 Instrumentation Theory 
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1.3.1 Single Dimension Liquid Chromatography 
Chromatography is a chemical technique that allows for the separation of 
components of a mixture. This is done through the use of a liquid mobile phase and a 
stationary phase. Different chemical compounds will have different affinities for these 
phases, and separate based on those affinities. Compounds with a higher affinity for the 
mobile phase will travel faster, and those with a higher affinity for the stationary phase 
will travel slower. The majority of liquid chromatographic separations involve the use of 
reverse-phase chromatography, where the mobile phase is polar and the stationary phase 
is non-polar.42  
There are a variety of liquid chromatography methods that may be employed, 
with HPLC and UPLC being two of the most commonly used methods. HPLC is a type 
of liquid chromatography that uses a stationary phase with a particle size typically 3-5 
µm in diameter within a column that is between 3 and 25 cm in length and 3-5 mm in 
internal diameter. UPLC uses reduced particle size that is capable of withstanding higher 
pressure. Depending on the brand of instrument, a typical HPLC system operates up to a 
limit of about 6000 psi of pressure, whereas the UPLC operates to a limit of about 18000 
psi. This allows for greater speed and resolution, which results in shorter run times than 
HPLC with improved  resolution.43 
1.3.2 Two-Dimensional Liquid Chromatography 
As a normal LC setup is known as one-dimensional (1D) liquid chromatography, 
the difference between the two types is the use of an additional column to add another 
layer of separation. Two-dimensional Liquid Chromatography (2D-LC) has traditionally 
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been used in proteomics and metabolomics, though the applications can vary.44 With 2D-
LC, either “heartcutting” or “comprehensive” chromatography can be performed.45 
“Comprehensive” chromatography involves transferring the whole elution onto the 
second column, while in “heartcutting” chromatography only the portion of interest of the 
sample is transferred.45,46  
Multidimensional chromatography also allows for techniques known as trap and 
elute, and AT-column dilution.47 The trap and elute method involves the use of two 
columns with distinctive chemistries. Analytes are first loaded directly onto the trap 
column, where they remain captured by the large particle size present in trap columns. 
Once the analytes are trapped on the column, a valve switch brings the trap column in the 
path of the elution stream. Analytes elute off the trap column and onto the higher 
resolution column on the back end of the LC configuration. Using a trap and elute 
method can provide better sensitivity and specificity than a traditional 1D method.47 
However, trap and elute can typically only be performed on analytes dissolved in 
an aqueous component. This is because the organic component has too strong an affinity 
for the mobile phase, and a significant amount of the analyte spreads into the sorbent bed. 
For a Gaussian peak shape to be obtained post-separation, the analyte must remain in a 
tight and narrow band, which organic injections would not allow. AT-column dilution is 
a technique that allows for the injection of 100% organic samples into this trap and elute 
method. In an AT-column dilution method, dual streams are used to push a 100% organic 
sample from the injection port onto the first dimension. The flow rates from the two 
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pumps can be set to produce an optimal dilution ratio that would allow the organic 
injections to retain a Gaussian peak shape with the trap and elute method.47 
1.3.3 1D vs. 2D Chromatography 
One of the greatest advantages of 2D chromatography as opposed to 1D 
chromatography is the time saved on sample preparation. Typical sample preparation 
methods require the use of evaporation and reconstitution steps after the solid phase 
extraction (SPE) steps. The ability to use AT-column dilution to dilute 100% organic 
samples allows one to inject the elution from solid phase extraction without these time 
consuming steps. It also leads to a reduction in evaporative loss that may occur from this 
step.47,48 Screening methods are best when quick and sensitive, and as such 2D 
chromatography methods can be particularly helpful for this purpose. 2D 
chromatography often has superior resolution and specificity, particularly in complex 
samples.45,46  
1.3.4 Mass Spectrometry 
Mass spectrometry is a technique that can be used for identification and 
quantitation of samples to determine the identity of compounds within a sample. A mass 
spectrometer works by ionizing and fragmenting compounds. The ionized fragments are 
then separated by a mass analyzer according to their mass to charge ratio. Depending on 
what ionic fragments are produced and the abundance of those fragments, a compound 
can be qualitatively analyzed using a mass spectrometer.49 
In this analysis, HPLC and UPLC systems are coupled to a mass spectrometer. In 
order for a mass spectrometer to analyze the mass of a molecule, it first needs to be 
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converted into a gas-phase ion.50 As such, the liquid from an LC system is converted to 
the gas phase of matter during the ionization process. This process is referred to as 
atmospheric pressure ionization. The most common type is referred to as electrospray 
ionization. In electrospray ionization, the liquid is pumped through a charged capillary. 
Upon exiting the capillary, the liquid aerosolizes, and the droplets shed ions that flow into 
the mass spectrometer.49,50 
The next portion of the mass spectrometer is the mass analyzer. A quadrupole 
mass analyzer was used to optimize the chromatography parameters, but a time-of-flight 
(TOF) mass analyzer is used for the actual analysis. A quadrupole mass analyzer, uses a 
series of four conducting rods held parallel to the path of the ions. A fixed direct current 
and an oscillating radio frequency are applied to the rods, generating an electrical field. 
At a certain ratio of the direct current to radio frequency, only ions within a certain mass 
to charge ratio (m/z) range can travel through the mass analyzer. Anything outside of that 
ratio will collide with the rods. This ratio can be set to allow only a specific ion through, 
a process known as single ion monitoring.49,50 A triple quadrupole mass analyzer, like the 
one used in this analysis, has three sets of quadrupole filters, allowing for increased 
functionality. Only the first and third are used as mass analyzers. The middle quadrupole 
is under higher pressure and is used for fragmentation by collision induced dissociation. 
The first and third can be set to allow only specific ions through, a precursor ion and 
product ion. This process is known as multiple reaction monitoring (MRM) and allows 
for better selectivity, sensitivity and specificity.50 A TOF mass analyzer involves 
accelerating ions towards the detector. Ions with lower mass travel at faster speeds, and 
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thus take less time to reach the detector. A TOF analyzer can detect different ions within 
nanoseconds of each other. This can allow for a resolution that can determine an exact 
mass.50 
1.4 Research Objective 
The objective of this research is to develop a quick and sensitive method for the 
presumptive detection of the compounds used in sports doping. This was accomplished 
through the use of multidimensional liquid chromatography and time-of-flight mass 
spectrometry. 
  
19 
 
2. MATERIALS AND METHODS 
2.1 Materials 
2.1.1 Classes Developed for Analysis 
 Nine different classes of compounds, each containing between seven and eleven 
compounds, were chosen for analysis. These classes contain compounds representing 
seven different classes delineated by the World Anti-Doping Agency 2017 prohibited 
list.7  
2.1.2 Anabolic Agents Evaluated 
 Eight anabolic agents were evaluated for this research: 5α-Dihydrotestosterone, 
Androstenedione, Clenbuterol, Danazol, Epitestosterone, Testosterone, Tibolone, and 
Trans-Androsterone (Figure 1). The compounds were chosen based on availability.  
 
Figure 1: Structure of Anabolic Agents Analyzed51 
2.1.3 Beta 2 Agonists Evaluated 
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 Seven β2 agonists were evaluated for this research: Bambuterol, Fenoterol, 
Indacaterol, Isoproterenol, Isoxsuprine, Salbutamol, and Salmeterol (Figure 2). The 
compounds were chosen based on availability. 
 
Figure 2: Structure of Beta 2 Agonists Analyzed51 
2.1.4 Diuretics and Masking Agents Evaluated 
 Seven diuretics and masking agents were evaluated for this research: Amiloride, 
Bumetanide, Canrenone, Chlorthalidone, Furosemide, Metolazone, and Probenecid 
(Figure 3). The compounds were chosen based on availability. 
 
Figure 3: Structures of Diuretics and Masking Agents Analyzed 
2.1.5 Stimulants Evaluated 
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 Eight stimulants were evaluated for this research: Amphetamine, Butylone, 
Cathinone, Cocaine, Ephedrine, MDMA, Mephedrone, and Methamphetamine (Figure 4). 
The compounds were chosen based on availability. 
 
Figure 4: Structures of Stimulants Analyzed51,52 
2.1.6 Narcotics Evaluated 
 Nine narcotics were evaluated for this research: Codeine, Dihydrocodeine, 
Fentanyl, Heroin, Hydromorphone, Methadone, Morphine, Oxycodone and Pethidine 
(Figure 5). The compounds were chosen based on availability. 
 
Figure 5: Structures of Narcotics Analyzed51 
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2.1.7 Beta Blockers Evaluated 
 Eight beta blockers were evaluated for this research: Atenolol, Betaxolol, 
Carvedilol, Esmolol, Labetalol, Metoprolol, Propranolol, and Timolol (Figure 6). The 
compounds were chosen based on availability. 
 
Figure 6: Structures of Beta Blockers Analyzed51 
2.1.8 Phenethylamines Analyzed 
 Ten phenethylamines were evaluated for this research: 25N-NBOMe, 
Phentermine, Mescaline, 25D-NBOMe, 5-APB, 2C-H, 25I-NBOMe, 25C-NBOMe, 2C-I, 
and 2C-B (Figure 7). The compounds were chosen based on availability. 
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Figure 7: Structures of Phenethylamines Analyzed51 
2.1.9 Benzodiazepines Analyzed 
 Eleven benzodiazepines were evaluated for this research: Diazepam, Clobazam, 
Alprazolam, Bromazepam, Clonazepam, Chlordiazepoxide, Flunitrazepam, Oxazepam, 
Triazolam, Nordiazepam, and Temazepam (Figure 8). The compounds were chosen 
based on availability. 
 
Figure 8: Structures of Benzodiazepines Analyzed51,53 
2.1.10 Piperazines Analyzed 
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 Eleven piperazines were evaluated for this research: 1-Benzylpiperazine (BZP), 
2,3-Dichlorophenylpiperzine (DCPP), 4-Methyl-1-benzylpiperazine (MBZP), 1,4-
Dibenzylpiperazine (DBZP), 3-Chlorophenylpiperazine (mCPP), 4-
Methoxyphenylpiperazine (MeOPP), 4-Chlorophenylpiperazine (pCPP), 4-
Fluorophenylpiperazine (pFPP), 3-Trifluoromethylphenylpiperazine (TFMPP), 4-
Fluorobenzylpiperazine, and Phenylpiperazine (Figure 9). These compounds were chosen 
based on availability. 
 
Figure 9: Structures of Piperazines Analyzed51 
2.1.11 Standards and Reagents 
The compounds used for analysis were obtained from three different sources. 
dihydrotestosterone, clenbuterol, danazol, androstenedione, tibolone, testosterone, 
fenoterol, indacaterol, isoxsuprine, bambuterol, salmeterol aminoglutethimide, cyclofenil, 
formestane, letrozole, raloxifene, tamoxifen, toremifene, clomiphene, probenecid, 
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bumetanide, canrenone, chlorthalidone, furosemide, metolazone, butylone, fentanyl, 
methadone, morphine, oxycodone, betaxolol, timolol, carvedilol, esmolol, labetalol, 25I-
NBOMe, 25C-NBOMe, phentermine, mescaline, alprazolam, clonazepam, flunitrazepam, 
oxazepam, nordiazepam, temazepam, BZP, DCPP, DBZP, MBZP, mCPP, MeOPP, 
pCPP, pFPP, TFMPP, 4-fluoro BZP, and Phenylpiperazine were obtained from Cayman 
Chemical Company (Ann Arbor, MI, USA). Androsterone, isoproterenol, pethidine, 
salbutamol, amiloride, and propranolol were obtained from Sigma-Aldrich (St. Louis, 
MO, USA). Epitestosterone, cocaine, amphetamine, 3,4-
methylenedioxymethamphetamine (MDMA), methamphetamine, mephedrone, cathinone, 
ephedrine, codeine, hydromorphone, heroin, metoprolol, atenolol, 5-APB, and triazolam 
were obtained from Cerilliant Corporation (Round Rock, TX, USA). The solvents used 
for this analysis were methanol (MeOH), acetonitrile (ACN), ammonium hydroxide 
(NH4OH), and formic acid (FA). All solvents were Optima grade and obtained from 
Thermo Fisher Scientific (Waltham, MA, USA). Both Optima grade water and MilliQ 
grade water were used for this analysis. The Optima grade water was obtained from 
Thermo Fisher Scientific (Waltham, MA, USA) and the MilliQ grade water was obtained 
from EMD Millipore Sigma (Darmstadt, Germany). 
2.1.12 Instrumentation and Software 
An ACQUITY UPLC® (Waters Corporation, Milford, MA, USA) was utilized in 
the 2D configuration. Three pumps were used for this 2D configuration. The first pump, 
the loading pump, loaded the samples from the injection loop into a 50 microliter (µL) 
mixer at a rate of 0.1 mL/min. The second pump was a diluter pump that pumped water 
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into the 50 µL mixer at a rate of 2 mL/min. This second pump created the AT-column 
dilution effect. The third pump utilized was an elution pump, containing both an organic 
stream and an aqueous stream. Two detectors were used in this analysis, one for method 
optimization and one for analysis. The detector used for the method optimization process 
was a tandem MS, Xevo Triple Quadrupole (TQS) (Waters Corporation, Milford, MA, 
USA). The detector used for analysis was a Xevo G2-S TOF (Waters Corporation, 
Milford, MS, USA). The software utilized was MassLynx© version 4.2 (Waters 
Corporation, Milford, MA, USA). It was used to carry out analyses on the instrument, 
visualize the mass spectra and chromatograms produced, and perform data analysis. 
2.2 Methods 
2.2.1 Multiple Reaction Monitoring Optimization 
 Direct infusion was performed using a 100 ng/mL solution of each compound 
prepared in 50:50 water: methanol. Infusions were performed one after the other. A 
precursor ion was determined for each compound in MS1 scan mode and product ions 
were determined in MS/MS mode. The two most intense product ions were selected. 
Collision energy was optimized for each compound. Increasing the collision energy 
caused the precursor ion to fragment, leading to product ions in the mass spectra 
produced. The product ion with the highest intensity was chosen for quantitation. A 
second product ion, with the second highest intensity, was chosen for qualification. The 
capillary voltage, source temperature, desolvation temperature, desolvation gas rate, and 
cone gas rate were kept at constants of 3.0 kilovolts (kV), 150 degrees Celsius (°C), 
350°C, 1100 liters per hour (L/hr) and 150 L/hr, respectively. The optimized values for 
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the seven classes are displayed in separate multiple reaction monitoring (MRM) tables 
below (Tables 1-9). In each table, the first product ion listed is the quantitation ion, and 
the second ion listed is the qualification ion. 
 
Table 1: MRM Compound Optimization Table for Anabolic Agents. Transitions 
were determined for all standards. 
 
 
Compound Ion Mode Parent Ion Cone Voltage (V) Daughter Ions CE (eV)
105.2 30
159.3 20
132.2 25
203.2 15
253.4 15
271.5 15
310.3 20
148.1 25
109.4 25
269.4 15
295.3 10
277.2 15
255.4 10
161.3 15
109.2 25
253.4 15
Trans-Androsterone ESI+ 273.4 30
Epitestosterone ESI+ 288.4 30
Danazol ESI+ 338.4 30
5α-Dihydrotestosterone ESI+ 291.5
Testosterone ESI+ 289.4 30
Androstenedione ESI+ 287.4 30
Tibolone ESI+ 313.5 30
30
Clenbuterol ESI+ 277.3 30
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Table 2: MRM Compound Optimization Table for Beta 2 Agonists. Transitions were 
obtained for all standards. 
 
Table 3: MRM Compound Optimization Table for Diuretics and Masking Agents. 
Transitions were obtained for all standards. 
 
Compound Ion Mode Parent Ion Cone Voltage (V) Daughter Ions CE (eV)
222.3 10
148.2 20
107.2 30
135.3 15
194.2 10
152.1 15
375.2 15
145.2 30
284.3 15
107.3 25
294.3 20
312.3 15
398.3 15
380.4 20
ESI+ 368.3 30Bambuterol
Salmeterol
ESI+ 240.3 30
ESI+ 304.3 30
ESI+ 212.2
Isoxsuprine
ESI+ 416.4 30
ESI+ 302.3 30
Salbutamol
Fenoterol
Isoproterenol
Indacaterol
30
ESI+ 393.2 30
Compound Ion Mode Parent Ion Cone Voltage (V) Daughter Ions CE (eV)
116.1 30
143 25
244.2 10
202.2 15
240.3 15
284.4 15
107.2 30
187.3 20
241.1 20
243 20
309.3 10
273.3 15
259.2 20
179.2 30
30
30
ESI+ 322.2 30
ESI+ 353.1 30
Chlorthalidone
Furosemide
Metolazone
Canrenone ESI+ 341.5
ESI+ 366.3
Amiloride
Probenecid 
Bumetanide
286.3 30
ESI+ 365.3
ESI+ 230.2 30
ESI+
30
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Table 4: MRM Optimization Table for Stimulants. Transitions were obtained for each 
standard. 
 
Compound Ion Mode Parent Ion Cone Voltage (V) Daughter Ions CE (eV)
182.4 20
105.2 30
119.2 10
91.2 15
163.3 10
133 20
91.3 15
119.3 10
160.3 10
145.3 20
132.2 10
117.2 20
174.1 20
204.3 10
148.2 10
133.3 20
30
30
ESI+ 150.3 30
ESI+ 222.2 30
Cathinone
Butylone
Ephedrine
ESI+ 304.4
Mephedrone ESI+ 178.3
ESI+ 166.3
Cocaine
Amphetamine
MDMA
Methamphetamine
194.3 30
ESI+ 150.3
30
ESI+ 136.2 30
ESI+
30
30 
 
Table 5: MRM Compound Optimization Table for Narcotics. Transitions were 
determined for all standards. 
 
Compound Ion Mode Parent Ion Cone Voltage (V) Daughter Ions CE (eV)
215.2 25
165.2 35
185.2 30
157.1 40
165.2 40
268.3 30
188.2 20
105.1 30
265.3 15
105.1 25
201.3 25
165.1 35
298.2 20
256.2 20
220.3 20
174.3 20
199.2 30
201.3 25
30
ESI+ 316.3 30
ESI+ 248.3 30
30Morphine
Oxycodone
337.3 30
ESI+ 310.4 30
Pethidine
Dihydrocodeine
ESI+ 300.3
ESI+ 286.3
ESI+ 370.3
Methadone
ESI+ 286.4
ESI+ 302.3
Codeine
Hydromorphone
Diamorphine (Heroin)
Fentanyl
30
30
30
ESI+
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Table 6: MRM Compound Optimization for Beta Blockers. Transitions were obtained 
for all standards. 
 
Compound Ion Mode Parent Ion Cone Voltage (V) Daughter Ions CE (eV)
116.4 20
133.2 25
183.3 20
157.2 20
190.2 20
144.9 25
116.2 20
121.3 25
261.1 15
244.2 20
100.3 30
224.2 20
145.2 20
219.3 20
162.1 25
311.3 10
30
30
ESI+ 407.3 30
ESI+ 296.4 30
Carvedilol
Esmolol
Labetalol
ESI+ 268.4
Timolol ESI+ 317.4
ESI+ 329.4
Metoprolol
Propranolol
Atenolol
Betaxolol
267.4 30
ESI+ 308.4
30
ESI+ 260.3 30
ESI+
30
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Table 7: MRM Compound Optimization for Phenethylamines. Transitions were 
obtained for all standards. 
 
Compound Ion Mode Parent Ion Cone Voltage (V) Daughter Ions CE (eV)
121.3 20
272.2 15
121.3 20
199.3 15
91.2 15
133.3 10
180.3 15
165.2 20
159.3 10
131.1 15
242.9 15
228.0 10
165.2 10
150.2 15
291.1 15
276 20
121.3 15
272.4 15
121.3 20
179.3 15
30
347.4 30
ESI+ 316.4 3025D-NBOMe
ESI+ 308.1 30
150.3 30
ESI+ 195.3 30
ESI+ 176.3 30
260.0 30
ESI+ 182.2
ESI+
ESI+
2C-B
2C-H
2C-I
25N-NBOMe
25I-NBOMe
25C-NBOMe
Phentermine
Mescaline
ESI+
ESI+
ESI+
5-APB
428.2 30
336.3 30
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Table 8: MRM Compound Optimization for Benzodiazepines. Transitions were 
obtained for all standards. 
 
Compound Ion Mode Parent Ion Cone Voltage (V) Daughter Ions CE (eV)
281.3 25
205.2 30
270.3 25
241.3 30
268.2 25
239.3 30
308.2 25
315.1 30
269.2 15
241.2 20
140.1 25
243.2 20
283.2 15
255.3 20
182.3 30
209.1 25
282.1 20
227.1 25
259.1 20
224.2 30
154.2 25
193.3 30
30
ESI+ 318.2 30
ESI+ 285.2 30
ESI+ 300.2 30
ESI+ 301.2 30
30
Nordiazepam
Temazepam
316.3 30
ESI+ 314.2 30
ESI+ 287.1 30
ESI+ 271.2 30
ESI+ 301.3
Bromazepam
Chlordiazepoxide
Clobazam
Diazepam
Alprazolam
Clonazepam
Flunitrazepam
Triazolam
Oxazepam
ESI+ 309.4 30
ESI+
ESI+ 343.2
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Table 9: MRM Compound Optimization for Piperazines. Transitions were obtained 
for all compounds. 
 
2.2.2 Chromatography Method Development 
One stock solution per class was prepared for chromatography method 
development. Each solution contained every compound from its assigned class, forming a 
final concentration for each compound, of 10 micrograms per milliliter (µg/mL). Serial 
dilutions were prepared on each stock solution to prepare solutions of lower 
concentration. This resulted in 10 nanograms per milliliter (ng/mL) solutions prepared in 
MeOH, ACN and MilliQ water. These solutions were analyzed on 36 different methods 
with varying combinations of trap columns, loading conditions and elution conditions. 
Compound Ion Mode Parent Ion Cone Voltage (V) Daughter Ions CE (eV)
91.2 20
85.2 15
188.2 20
153.2 25
175.3 20
134.3 25
91.3 20
99.2 15
154.1 20
119.3 20
150.1 20
119.2 20
154.2 10
119.3 20
138.2 20
136.2 20
188.2 20
119.1 30
109.2 20
85.2 15
120.3 15
77.1 25
30
ESI+ 181.3 30
ESI+ 163.3 30
ESI+ 231.3 30
ESI+ 195.4 30
30
4-Methoxyphenylpiperazine (MeOPP)
4-Chlorophenylpiperazine (pCPP)
231.1 30
ESI+ 267.3 30
ESI+ 197.3 30
ESI+ 193.4 30
ESI+ 197.2
4-Fluorophenylpiperazine (pFPP)
3-Trifluoromethylphenylpiperazine (TFMPP)
4-fluoro BZP
Phenyl Piperazine
1-Benzylpiperazine (BZP)
2,3-Dichlorophenylpiperazine (DCPP)
1,4-Dibenzylpiperazine (DBZP)
4-Methyl-1-benzylpiperazine (MBZP)
3-Chlorophenylpiperazine (mCPP)
ESI+ 177.3 30
ESI+
ESI+ 190.3
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The injection volume for each sample was kept at a constant 50 µl. Also kept constant 
were the loading flow rate and dilution flow rate at values of 0.1 milliliters per minute 
(mL/min) and 2.0 mL/min, respectively. Samples were loaded onto the trap column at a 
rate of 2.0 mL/min. From this column, the samples were eluted at a rate of 0.5 mL/min 
with a linear gradient elution that started at 95% water and 5% organic. This gradient was 
performed for 5.0 minutes and held at 95% organic for one minute, before returning on a 
0.5 linear gradient back to 95% water and 5% organic. This resulted in a chromatography 
run totaling 10 minutes in length.  
Thirty-six different methods that involved four distinct variables were tested on 
each class of compounds. These methods involved comparing two different elution 
solvents; MeOH and ACN, three different loading pH levels; 3, 7, and 10; and two 
different elution pH levels; a low of pH 3 and a high of pH 10. FA was used to create the 
acidic conditions and NH4OH was used to create basic conditions. Finally, three trap 
columns of differing retention strengths were analyzed, a Waters ACQUITY UPLC 
hydrophilic-lipophilic balance (HLB), 2.1 x 30 mm, 20 µm; a Waters ACQUITY UPLC 
ethylene bridged hybrid (BEH) C18, 2.1 x 30 mm, 10 µm; and a Waters ACQUITY 
UPLC BEH C8, 2.1 x 30 mm, 10 µm. The analytical column was kept constant, with a 
Waters ACQUITY UPLC BEH C18, 2.1 x 50 mm, 1.7 µm. Figure 10 provides a visual 
example of these methods, delineating the 36 permutations analyzed. 
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Figure 10: 6 X 6 Method Optimization Scheme54 
Each sample was injected three times and the third injection for each was 
analyzed for chromatography evaluation. The system was automated to run these samples 
overnight, allowing chromatography method optimization to be completed in 18 hours.  
In order to determine the optimal chromatography method for each class of 
compounds, the chromatograms produced were examined to determine their quality. 
Upon examination, chromatograms were divided into three distinct groups, defined by 
color. Green chromatograms were those with Gaussian peak shape. Yellow 
chromatograms are those with a peak that is unsuitable for quantitation. This can mean 
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that the peak has significant leading or tailing, or that it is a split peak. Red 
chromatograms are those in which no signal was detected. Examples of each type of 
chromatogram can be seen in figures 11, 12 and 13 
Figure 11: Example of a Green Chromatogram 
 
Figure 12: Example of a Yellow Chromatogram. Significant tailing can be observed. 
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Figure 13: Example of a Red Chromatogram. No peak can be distinguished from the 
noise. 
 
All classes of compounds were evaluated in this manner. The method(s) for which 
peaks were visible for the greatest amount of compounds were chosen to optimize the 
extraction process. When necessary, methods that produced Gaussian peaks for more 
compounds were given preference over those that produced non-Gaussian peaks. 
2.2.3 Limit of Detection Determination 
 The limit of detection for each compound was determined using the optimal 
chromatography methods obtained from the previous chromatography optimization 
process. Standards were prepared at five concentrations: 1 picogram per milliliter 
(pg/mL), 10 pg/mL, 100 pg/mL, 1 ng/mL and 10 ng/mL for the triple quadrupole MS, 
and 100 pg/mL, 1 ng/mL, 10 ng/mL, 100 ng/mL, and 1 µg/mL for the TOF MS. These 
standard concentrations were prepared in both ACN and MeOH. Both sets (ACN and 
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MeOH) were injected in triplicate. The limit of detection was determined as the lowest 
concentration at which a S/N greater than 3:1 was acquired, in accordance with the 
standard practices for method validation in forensic toxicology.55   
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3. RESULTS AND DISCUSSION 
3.1 Anabolic Agents 
 As previously mentioned, the chromatograms produced during method 
development portion were analyzed to determine their quality. Details of what the 
methods entailed can be found in appendix A. The results for chromatography method 
optimization on the anabolic agents of class 1 can be found in Appendix A. Methods 20 
and 23 were observed to have a Gaussian peak shape for each compound, regardless of 
the solvent used for injection. Methods 2 and 19 were observed to have a Gaussian peak 
shape for each compound when MeOH or ACN was the solvent used for injection. Of the 
compounds included in the anabolic agent group and when water was the solvent used, 
tibolone was the only compound in which no signal was observed. As this method begins 
with a SPE step, from which the final result should be a 100% organic elution. Thus, this 
negative for result for tibolone should not be used to discount method 2 or method 19 as 
viable chromatography methods for this class of compounds. On their own, the 
recommended method for anabolic agents would be method 23. The reasoning for this is 
that the use of a neutral loading pH means a lab can conserve their acidic additive. 
However, anabolic agents can share a chromatography method with any other class of 
compounds for which methods 2, 19, 20 or 23 produce acceptable chromatography. 
3.2 Beta 2 Agonists 
 The results of the chromatography method optimization of the β2 agonists can be 
found in appendix A. Details of what the methods entailed can be found in appendix A. 
None of the 36 methods evaluated produced Gaussian peaks for every compound 
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regardless of solvent. However, there are methods for which at least one solvent produces 
a Gaussian peak for every compound. Those methods are method 1, 2 and 6. As these 
methods were evaluated for screening purposes, methods in which any peak was 
produced, Gaussian or otherwise, could also be used. Therefore, method 3, 9, 23 could 
also be used. Considering no other compounds, the most optimal method for β2 agonists 
would be method 6, as the neutral pH elution would allow a lab to conserve the amount 
of additives used during analysis. 
3.3 Diuretics and Masking Agents 
  The results of the chromatography method optimization of the diuretics and 
masking agents can be found in appendix A. Details of what the methods entailed can be 
found in appendix A. No method produced a Gaussian peak for every compound 
regardless of solvent. There were some methods for which a Gaussian peak was produced 
for at least one organic solvent. Those methods included method 2, 6, and 19. Methods 
that could be used for screening but that do not produce a Gaussian peak for each 
compound include 5, 11, 22, 28, 30, 31 and 32. As method 6 involves loading at a neutral 
pH, it is the optimal method for analysis of these compounds, as it is the most 
conservative in terms of additives. 
3.4 Stimulants 
 The results for the chromatography optimization for the stimulants can be found 
in appendix A. Details of what the methods entailed can be found in appendix A. The 
methods for which stimulants produce a Gaussian peak regardless of the solvent injected 
are methods 6, 8, 24, 25, 27, and 35. Methods for which at least one organic solvent 
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produced a Gaussian peak include methods 7, 9, 14, 17, 31, 32, and 34. Methods that 
could be used for screening purposes but that do not produce Gaussian peak shapes for 
each compound are methods 15, 16, 18, 22, 33 and 36. This accounts for a total of 19 
methods out of a possible 36, meaning that the screening method used for these 
compounds can be adaptable to whatever other compounds also need to be screened. 
3.5 Narcotics 
 The results for the chromatography optimization for the stimulants can be found 
in appendix A. Details of what the methods entailed can be found in appendix A. No 
method produced a Gaussian peak for every compound regardless of solvent. There were 
some methods for which a Gaussian peak was produced for at least one organic solvent. 
These methods included methods 1, 2, 4, 7, 8, 13, 14, 15, 17, 18, 19, 26, 32, and 35. 
Methods that could be used for screening purposes but that do not produce Gaussian peak 
shapes for each compound are methods 3, 5, 6, 9, 10, 11, 12, 20, 21, 22, 23, 24, 25, 27, 
28, 29, 31, 33, 34, and 36. Only two methods do not produce a peak for at least one 
compound in organic solvent. Of those, the one compound for method 16 that does not 
produce a chromatographic peak when injected in organic solvent, hydromorphone, 
produces a chromatographic peak when injected in water. As such, for chromatographic 
methods, these narcotics are adaptable towards whatever method is required for other 
compounds that are being screened. 
3.6 Beta Blockers 
 The results for the chromatography optimization for the stimulants can be found 
in appendix A. Details of what the methods entailed can be found in appendix A. There 
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were nine chromatography methods that produced Gaussian peak shapes for every 
compound in this class regardless of the solvent injected. Those methods were methods 2, 
6, 8, 9, 16, 17, 19, 25, 32, and method 35. Furthermore, methods 1, 3, 7, 14, 23, 24, 31 
and 34 all produced a Gaussian peak for each beta blocker compound in at least one 
organic solvent injection. Also, methods 5, 11, 13, 15, 18, 21, 22, 27, 28, 29, 30, 33, and 
36 produce a peak for each compound in at least one organic solvent. As such, a grand 
total of 32 chromatographic methods can be used for qualitative purposes. Thus, they are 
adaptable to whatever other compounds are meant to be included in the screening 
process. 
3.7 Phenethylamines 
 The results for the chromatography optimization for the stimulants can be found 
in appendix A. Details of what the methods entailed can be found in appendix A. There 
were seven chromatography methods that produced Gaussian peak shapes for every 
compound in this class regardless of the solvent injected. Those methods were methods 6, 
7, 8, 9, 14, 17, and 26. Other methods, in which a Gaussian peak was produced for each 
compound in at least one organic solvent, include methods 3, 13, 16, 19, 20, 21, 23, 24, 
25, 27, 29, and 34. Finally, the methods that produce a peak, Gaussian or otherwise, for 
each compound are methods 11, 15, 18, and 36. This is a total of 26 chromatographic 
methods out of the 36 tested, meaning that these compounds are adaptable to other 
groups of compounds. 
3.8 Benzodiazepines 
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 When it comes to chromatography, benzodiazepines are a highly adaptable class 
of compounds. Details of what the methods entailed can be found in appendix A. In 35 of 
the 36 methods tested, every benzodiazepine compound produced a peak. Furthermore, 
each compound produced a Gaussian peak, regardless of injection solvent, for 22 of the 
methods tested. Those methods were methods 1, 2, 5, 9, 10, 11, 13, 15, 16, 18, 19, 20, 22, 
23, 25, 26, 28, 29, 31, 32, 34 and 35. An additional 7 methods produced a Gaussian peak 
for each compound in at least one organic solvent: methods 3, 4, 6, 7, 8, 12 and 14. These 
compounds produced tailing peaks when injected onto a HLB trap column and eluted 
with methanol. Therefore, while not ideal, methods 21, 24, 27, 30, 33, and 36 could be 
used as chromatography methods for screening purposes as well. These results can be 
found in appendix A. 
3.9 Piperazines 
 Unlike the benzodiazepines, the piperazines are not the most chromatographically 
adaptable group of compounds. Of the 36 methods tested, none produced a Gaussian 
peak for each compound, regardless of solvent injected. There were four methods that 
produced at Gaussian peak for each compound for at least one organic solvent injection. 
Those methods were methods 7, 9, 24, and 26. Also, method 27 produced a Gaussian 
peak for each compound in at least one solvent, though for 4-fluoro BZP it was only the 
water injection. There were no other methods for which a peak was produced for all 
compounds. These results can be found in appendix A. Details of what the methods 
entailed can be found in appendix A. 
3.10 Chromatography Combination 
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 When it comes to screening methods, the two most important factors are 
sensitivity and speed. Thus, the best case scenario for this research would be if one 
method produced high signals for every single compound. Unfortunately, none of the 36 
methods tested in this study were able to perform this task. As such, the importance 
became to determine a small combination of methods that were sensitive for the largest 
amount of compounds. While there are a variety of combinations that could be used, the 
three chosen were methods 6, 9 and 19. Details of what those methods entailed can be 
found in Appendix A. When injected a concentration of 10 ng/mL, at least one of those 
three methods produced a high signal for 64 of the 79 compounds tested in this analysis. 
Of the remaining 15 compounds, at least one of these three methods produced Gaussian 
peaks for 14 of the compounds. The only compound tested that does not produce a 
Gaussian peak for one of those three methods is morphine. Morphine produces a peak 
with a shoulder for all three methods. However, the peaks produced were of a higher 
signal than the Gaussian peaks for morphine produced by other methods. As each method 
takes 10 minutes, this combination of methods could be finished in little over a half of an 
hour.  
3.11 Chromatography Results 
 Limit of detection studies were run for each class on both the TQS system and the 
TOF in parallel. Figures 14 and 15 showcase the chromatograms produced for the 
phenethylamine compounds on the TQS system. At the shown concentration of 1 ng/mL, 
signals were seen, most with intensities in the range of e6 to e7. The only compound with 
a lower signal, is phentermine, which shows a signal intensity in the e5 range. Figure 16 
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shows the chromatograms produced by the varying 10X dilutions of one compound, 25I-
NBOMe. A peak with a reproducible RT and a S/N greater than 3:1 can be seen down to 
a concentration of 0.001 ng/mL, or 1 pg/mL. The 10 ng/mL concentration exhibited 
oversaturation of the detector, indicating the upper limit of detection was in the 1 ng/mL-
10 ng/mL range. Similar results were observed with 25N-NBOMe, 25C-NBOMe, and 
25D-NBOMe. 5-APB, 2C-B, 2C-H and 2C-I were observed to have peaks down to a 
concentration of 10 pg/mL. Phentermine was observed down to a concentration of 100 
pg/mL. All those concentrations were regardless as to whether the injection solvent was 
methanol or acetonitrile. For mescaline, there was a difference observed based on the 
injection solvent. When the injection solvent was methanol, the lowest concentration for 
which a peak was observed was 100 pg/mL. When the injection solvent was acetonitrile, 
the lowest concentration for which a peak was observed was 10 pg/mL. 
 Figure 17 shows the total ion chromatogram for a 1 µg/mL injection of the 
phenethylamine class and three chromatograms, each representative of a compound in 
that class. Those three compounds are 25I-NBOMe, phentermine and mescaline. Figures 
18 and 19 show those same chromatograms when injected at concentrations of 10 ng/mL 
and 1 ng/mL, respectively. Peaks for each of these compounds can still be observed at the 
same RT and at a S/N greater than 3:1. Similar results were seen in the other compounds 
from that class.    
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Figure 14: TQS Chromatograms for 5 Phenethylamine Compounds. A concentration of 
10 ng/mL is shown. The retention time of mescaline is 4.21. 
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Figure 15: TQS Chromatograms for 5 Remaining Phenethylamine Compounds. A 
concentration of 1 ng/mL is shown. 
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Figure 16: Limit of Detection Chromatograms for 25D-NBOMe. 
 
 
 
 
 
 
 
 
 
 
50 
 
 
Figure 17: TOF MS Chromatograms for Phenethylamine Compounds, 1 µg/mL. 
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Figure 18: TOF MS Chromatograms for Phenethylamine compounds, 10 ng/mL. 
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Figure 19: TOF MS Chromatograms for Phenethylamine Compounds, 1 ng/mL. 
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4. CONCLUSIONS 
A multidimensional liquid chromatography method for screening was optimized 
for 79 sports doping and drug of abuse compounds, divided into nine distinct classes of 
compounds. This method involved the use of three chromatographic methods. Those 
methods were: a pH 7 loading onto an HLB trap column, with a pH 3 water/acetonitrile 
gradient elution onto a C18 column; a pH 10 loading onto an HLB column with a pH 3 
water/acetonitrile gradient onto a C18 column; and a pH 3 loading onto a C8 column with 
a pH 3 water/methanol gradient onto a C18 column. Running all three of these methods 
could be completed in just over half an hour, allowing for sensitive results to be obtained 
on all 79 compounds included in this analysis. Results were obtained using both TOF and 
TQS MS. Regardless of the detection system used, the method could detect each 
compound. TOF MS allowed for the obtainment of an exact mass during spectrometry. 
Using the TQS in MRM mode allowed for the obtainment of lower limits of detection. As 
such, the two detectors would work best in tandem. TOF results, because of their exact 
mass, would be more useful to determine what compounds are present in an unknown 
sample. The TQS would be useful for quantitation, after a screening method is 
performed. 
Our proposed method has a few advantages over some of the currently use or 
proposed methods. After extraction, the Domímguez-Romero et al. uses evaporation and 
reconstitution steps.41 While extraction has yet to be optimized for our method, the results 
already seen with organic injections indicate that this step can be removed, saving the 
time necessary to perform it. Furthermore, when analyzing the 36 methods for the 
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chromatography optimization in our analysis, it was observed that, for a multitude of 
compounds, water injections consistently had a less intense signal than either methanol or 
acetonitrile. Therefore, it can be expected that our proposed analysis will result in lower 
limits of detection. The two chromatographic analyses are close in length, with their 
method requiring one 21-minute method that covers all of the compounds they analyzed, 
while our multi-method approach uses three methods that each take 10 minutes, requiring 
a half hour overall for separation. 
  
55 
 
5. FUTURE CONSIDERATIONS 
Time constraints prevented a full analysis of limit of detection and linearity. 
These factors, as well as other factors such as carryover, are the most immediate subjects 
to look into. 
The chromatography optimized here was performed using organic solvents. In 
actual practice, samples will be within biological matrices from which they will need to 
be extracted. Urine is the most commonly collected and analyzed sample matrix in the 
field of sports doping, though blood can also be analyzed. Therefore, the first 
consideration should be the optimization of extraction methods for urine, whole blood 
and plasma sample matrices. Although not routinely analyzed by WADA laboratories, it 
would also be beneficial to evaluate this method using alternative matrices such as oral 
fluid. 
The method presented in this study covers over 50 WADA prohibited compounds, 
though it has not been verified for the full prohibited list. Some of the studied classes of 
compounds, such as the anabolic agents, are designed to be similar in structure and 
chemical activity to one another. Therefore, the compounds from those classes not 
verified in this study should be expected to behave similarly under the chromatographic 
and extraction conditions presented. However, some of the studied classes, such as 
diuretics and masking agents, have varying structures and chemistries. The compounds 
from these classes should not be expected to behave similarly under the chromatographic 
and extraction conditions presented here. Furthermore, some of the compounds presented 
in this study have metabolites that may be present in a greater concentration than the 
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compounds presented here. These compounds, whether explicitly prohibited by WADA 
or not, should be included as their presence can indicate the presence of a WADA 
prohibited compound. Future studies should be performed on determining the screening 
process of all these compounds, and seeing how that process correlates to the screening 
process presented here. 
Finally, part of the study presented here determined the optimal chromatography 
and extraction conditions for a variety of classes of sports doping compounds. While 
utilized for screening purposes in this study, the methods presented here may also be 
useful in the quantitation of these compounds. Further studies should be taken on each 
class of compounds here to determine if the methods presented here are useful for the 
quantitation of these compounds, and if not, what method would be useful for 
quantitation. 
57 
 
APPENDIX A: Chromatography Evaluation 
Table A: Details of 36 Chromatographic Methods Tested 
 
Method Loading pH Trap Column Elution Solvent Elution pH Analytical Column
1 3 C8 ACN 3 C18
2 3 C18 ACN 3 C18
3 3 HLB ACN 3 C18
4 7 C8 ACN 3 C18
5 7 C18 ACN 3 C18
6 7 HLB ACN 3 C18
7 10 C8 ACN 3 C18
8 10 C18 ACN 3 C18
9 10 HLB ACN 3 C18
10 3 C8 ACN 10 C18
11 3 C18 ACN 10 C18
12 3 HLB ACN 10 C18
13 7 C8 ACN 10 C18
14 7 C18 ACN 10 C18
15 7 HLB ACN 10 C18
16 10 C8 ACN 10 C18
17 10 C18 ACN 10 C18
18 10 HLB ACN 10 C18
19 3 C8 MeOH 3 C18
20 3 C18 MeOH 3 C18
21 3 HLB MeOH 3 C18
22 7 C8 MeOH 3 C18
23 7 C18 MeOH 3 C18
24 7 HLB MeOH 3 C18
25 10 C8 MeOH 3 C18
26 10 C18 MeOH 3 C18
27 10 HLB MeOH 3 C18
28 3 C8 MeOH 10 C18
29 3 C18 MeOH 10 C18
30 3 HLB MeOH 10 C18
31 7 C8 MeOH 10 C18
32 7 C18 MeOH 10 C18
33 7 HLB MeOH 10 C18
34 10 C8 MeOH 10 C18
35 10 C18 MeOH 10 C18
36 10 HLB MeOH 10 C18
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Table B: Chromatography Evaluation for Class 1. Methods 1-9 
 
Method 1 2 3 4 5 6 7 8 9
Trap Column c8 c18 HLB c8 c18 HLB c8 c18 HLB
Loading pH 3 3 3 7 7 7 10 10 10
Elution pH 3 3 3 3 3 3 3 3 3
Elution Solvent ACN ACN ACN ACN ACN ACN ACN ACN ACN
5α-Dihydrotestosterone (Water)
5α-Dihydrotestosterone (MeOH)
5α-Dihydrotestosterone (ACN)
Clenbuterol (Water)
Clenbuterol (MeOH)
Clenbuterol (ACN)
Epitestosterone (Water)
Epitestosterone (MeOH)
Epitestosterone (ACN)
Danazol (Water)
Danazol (MeOH)
Danazol (ACN)
Androstenedione (Water)
Androstenedione (MeOH)
Androstenedione (ACN)
Tibolone (Water)
Tibolone (MeOH)
Tibolone (ACN)
Trans-Androsterone (Water)
Trans-Androsterone (MeOH)
Trans-Androsterone (ACN)
Testosterone (Water)
Testosterone (MeOH)
Testosterone (ACN)
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Table C: Chromatography Evaluation for Class 1. Methods 10-18 
 
 
Method 10 11 12 13 14 15 16 17 18
Trap Column c8 c18 HLB c8 c18 HLB c8 c18 HLB
Loading pH 3 3 3 7 7 7 10 10 10
Elution pH 10 10 10 10 10 10 10 10 10
Elution Solvent ACN ACN ACN ACN ACN ACN ACN ACN ACN
5α-Dihydrotestosterone (Water)
5α-Dihydrotestosterone (MeOH)
5α-Dihydrotestosterone (ACN)
Clenbuterol (Water)
Clenbuterol (MeOH)
Clenbuterol (ACN)
Epitestosterone (Water)
Epitestosterone (MeOH)
Epitestosterone (ACN)
Danazol (Water)
Danazol (MeOH)
Danazol (ACN)
Androstenedione (Water)
Androstenedione (MeOH)
Androstenedione (ACN)
Tibolone (Water)
Tibolone (MeOH)
Tibolone (ACN)
Trans-Androsterone (Water)
Trans-Androsterone (MeOH)
Trans-Androsterone (ACN)
Testosterone (Water)
Testosterone (MeOH)
Testosterone (ACN)
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Table D: Chromatography Evaluation for Class 1. Methods 19-27 
 
Method 19 20 21 22 23 24 25 26 27
Trap Column c8 c18 HLB c8 c18 HLB c8 c18 HLB
Loading pH 3 3 3 7 7 7 10 10 10
Elution pH 3 3 3 3 3 3 3 3 3
Elution Solvent MeOHMeOHMeOHMeOHMeOH MeOH MeOH MeOH MeOH
5α-Dihydrotestosterone (Water)
5α-Dihydrotestosterone (MeOH)
5α-Dihydrotestosterone (ACN)
Clenbuterol (Water)
Clenbuterol (MeOH)
Clenbuterol (ACN)
Epitestosterone (Water)
Epitestosterone (MeOH)
Epitestosterone (ACN)
Danazol (Water)
Danazol (MeOH)
Danazol (ACN)
Androstenedione (Water)
Androstenedione (MeOH)
Androstenedione (ACN)
Tibolone (Water)
Tibolone (MeOH)
Tibolone (ACN)
Trans-Androsterone (Water)
Trans-Androsterone (MeOH)
Trans-Androsterone (ACN)
Testosterone (Water)
Testosterone (MeOH)
Testosterone (ACN)
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Table E: Chromatography Evaluation for Class 1. Methods 28-36 
 
Method 28 29 30 31 32 33 34 35 36
Trap Column c8 c18 HLB c8 c18 HLB c8 c18 HLB
Loading pH 3 3 3 7 7 7 10 10 10
Elution pH 10 10 10 10 10 10 10 10 10
Elution Solvent MeOHMeOHMeOHMeOHMeOH MeOH MeOH MeOH MeOH
5α-Dihydrotestosterone (Water)
5α-Dihydrotestosterone (MeOH)
5α-Dihydrotestosterone (ACN)
Clenbuterol (Water)
Clenbuterol (MeOH)
Clenbuterol (ACN)
Epitestosterone (Water)
Epitestosterone (MeOH)
Epitestosterone (ACN)
Danazol (Water)
Danazol (MeOH)
Danazol (ACN)
Androstenedione (Water)
Androstenedione (MeOH)
Androstenedione (ACN)
Tibolone (Water)
Tibolone (MeOH)
Tibolone (ACN)
Trans-Androsterone (Water)
Trans-Androsterone (MeOH)
Trans-Androsterone (ACN)
Testosterone (Water)
Testosterone (MeOH)
Testosterone (ACN)
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Table F: Chromatography Evaluation for Beta 2 Agonists. Methods 1-9. 
 
Method 1 2 3 4 5 6 7 8 9
Elution pH Low Low Low Low Low Low Low Low Low
Loading pH 3 3 3 7 7 7 10 10 10
Trap Column c8 c18 HLB c8 c18 HLB c8 c18 HLB
Elution Solvent ACN ACN ACN ACN ACN ACN ACN ACN ACN
Salbutamol (H2O)
Salbutamol (MeOH)
Salbutamol (ACN)
Fenoterol (H2O)
Fenoterol (MeOH)
Fenoterol (ACN)
Isoproterenol (H2O)
Isoproterenol (MeOH)
Isoproterenol (ACN)
Indacaterol (H2O)
Indacaterol (MeOH)
Indacaterol (ACN)
Isoxsuprine (H2O)
Isoxsuprine (MeOH)
Isoxsuprine (ACN)
Bambuterol (H2O)
Bambuterol (MeOH)
Bambuterol (ACN)
Salmeterol (H2O)
Salmeterol (MeOH)
Salmeterol (ACN)
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Table G: Chromatography Evaluation for Beta 2 Agonists. Methods 10-18 
 
Method 10 11 12 13 14 15 16 17 18
Elution pH High High High High High High High High High
Loading pH 3 3 3 7 7 7 10 10 10
Trap Column c8 c18 HLB c8 c18 HLB c8 c18 HLB
Elution Solvent ACN ACN ACN ACN ACN ACN ACN ACN ACN
Salbutamol (H2O)
Salbutamol (MeOH)
Salbutamol (ACN)
Fenoterol (H2O)
Fenoterol (MeOH)
Fenoterol (ACN)
Isoproterenol (H2O)
Isoproterenol (MeOH)
Isoproterenol (ACN)
Indacaterol (H2O)
Indacaterol (MeOH)
Indacaterol (ACN)
Isoxsuprine (H2O)
Isoxsuprine (MeOH)
Isoxsuprine (ACN)
Bambuterol (H2O)
Bambuterol (MeOH)
Bambuterol (ACN)
Salmeterol (H2O)
Salmeterol (MeOH)
Salmeterol (ACN)
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Table H: Chromatography Evaluation for Beta 2 Agonists. Methods 19-27 
 
Method 19 20 21 22 23 24 25 26 27
Elution pH Low Low Low Low Low Low Low Low Low
Loading pH 3 3 3 7 7 7 10 10 10
Trap Column c8 c18 HLB c8 c18 HLB c8 c18 HLB
Elution Solvent MeOH MeOH MeOH MeOH MeOH MeOH MeOH MeOH MeOH
Salbutamol (H2O)
Salbutamol (MeOH)
Salbutamol (ACN)
Fenoterol (H2O)
Fenoterol (MeOH)
Fenoterol (ACN)
Isoproterenol (H2O)
Isoproterenol (MeOH)
Isoproterenol (ACN)
Indacaterol (H2O)
Indacaterol (MeOH)
Indacaterol (ACN)
Isoxsuprine (H2O)
Isoxsuprine (MeOH)
Isoxsuprine (ACN)
Bambuterol (H2O)
Bambuterol (MeOH)
Bambuterol (ACN)
Salmeterol (H2O)
Salmeterol (MeOH)
Salmeterol (ACN)
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Table I: Chromatography Evaluation for Beta 2 Agonists. Methods 28-36 
 
Method 28 29 30 31 32 33 34 35 36
Elution pH High High High High High High High High High
Loading pH 3 3 3 7 7 7 10 10 10
Trap Column c8 c18 HLB c8 c18 HLB c8 c18 HLB
Elution Solvent MeOH MeOH MeOH MeOH MeOH MeOH MeOH MeOH MeOH
Salbutamol (H2O)
Salbutamol (MeOH)
Salbutamol (ACN)
Fenoterol (H2O)
Fenoterol (MeOH)
Fenoterol (ACN)
Isoproterenol (H2O)
Isoproterenol (MeOH)
Isoproterenol (ACN)
Indacaterol (H2O)
Indacaterol (MeOH)
Indacaterol (ACN)
Isoxsuprine (H2O)
Isoxsuprine (MeOH)
Isoxsuprine (ACN)
Bambuterol (H2O)
Bambuterol (MeOH)
Bambuterol (ACN)
Salmeterol (H2O)
Salmeterol (MeOH)
Salmeterol (ACN)
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Table J: Chromatography Evaluation of Diuretics and Masking Agents. Methods 1-9 
 
Method 1 2 3 4 5 6 7 8 9
Elution pH Low Low Low Low Low Low Low Low Low
Loading pH 3 3 3 7 7 7 10 10 10
Trap Column c8 c18 HLB c8 c18 HLB c8 c18 HLB
Elution Solvent ACN ACN ACN ACN ACN ACN ACN ACN ACN
Amiloride (H2O)
Amiloride (MeOH)
Amiloride (ACN)
Probenecid (H2O)
Probenecid (MeOH)
Probenecid (ACN)
Bumetanide (H2O)
Bumetanide (MeOH)
Bumetanide (ACN)
Canrenone (H2O)
Canrenone (MeOH)
Canrenone (ACN)
Chlorthalidone (H2O)
Chlorthalidone (MeOH)
Chlorthalidone (ACN)
Furosemide (H2O)
Furosemide (MeOH)
Furosemide (ACN)
Metolazone (H2O)
Metolazone (MeOH)
Metolazone (ACN)
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Table K: Chromatography Evaluation for Diuretics and Masking Agents. Methods 10-18 
 
Method 10 11 12 13 14 15 16 17 18
Elution pH High High High High High High High High High
Loading pH 3 3 3 7 7 7 10 10 10
Trap Column c8 c18 HLB c8 c18 HLB c8 c18 HLB
Elution Solvent ACN ACN ACN ACN ACN ACN ACN ACN ACN
Amiloride (H2O)
Amiloride (MeOH)
Amiloride (ACN)
Probenecid (H2O)
Probenecid (MeOH)
Probenecid (ACN)
Bumetanide (H2O)
Bumetanide (MeOH)
Bumetanide (ACN)
Canrenone (H2O)
Canrenone (MeOH)
Canrenone (ACN)
Chlorthalidone (H2O)
Chlorthalidone (MeOH)
Chlorthalidone (ACN)
Furosemide (H2O)
Furosemide (MeOH)
Furosemide (ACN)
Metolazone (H2O)
Metolazone (MeOH)
Metolazone (ACN)
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Table L: Chromatography Evaluation for Diuretics and Masking Agents. Methods 19-27 
 
  
Method 19 20 21 22 23 24 25 26 27
Elution pH Low Low Low Low Low Low Low Low Low
Loading pH 3 3 3 7 7 7 10 10 10
Trap Column c8 c18 HLB c8 c18 HLB c8 c18 HLB
Elution Solvent MeOH MeOH MeOH MeOH MeOH MeOH MeOH MeOH MeOH
Amiloride (H2O)
Amiloride (MeOH)
Amiloride (ACN)
Probenecid (H2O)
Probenecid (MeOH)
Probenecid (ACN)
Bumetanide (H2O)
Bumetanide (MeOH)
Bumetanide (ACN)
Canrenone (H2O)
Canrenone (MeOH)
Canrenone (ACN)
Chlorthalidone (H2O)
Chlorthalidone (MeOH)
Chlorthalidone (ACN)
Furosemide (H2O)
Furosemide (MeOH)
Furosemide (ACN)
Metolazone (H2O)
Metolazone (MeOH)
Metolazone (ACN)
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Table M: Chromatography Evaluation for Diuretics and Masking Agents. Methods 28-36 
 
Method 28 29 30 31 32 33 34 35 36
Elution pH High High High High High High High High High
Loading pH 3 3 3 7 7 7 10 10 10
Trap Column c8 c18 HLB c8 c18 HLB c8 c18 HLB
Elution Solvent MeOH MeOH MeOH MeOH MeOH MeOH MeOH MeOH MeOH
Amiloride (H2O)
Amiloride (MeOH)
Amiloride (ACN)
Probenecid (H2O)
Probenecid (MeOH)
Probenecid (ACN)
Bumetanide (H2O)
Bumetanide (MeOH)
Bumetanide (ACN)
Canrenone (H2O)
Canrenone (MeOH)
Canrenone (ACN)
Chlorthalidone (H2O)
Chlorthalidone (MeOH)
Chlorthalidone (ACN)
Furosemide (H2O)
Furosemide (MeOH)
Furosemide (ACN)
Metolazone (H2O)
Metolazone (MeOH)
Metolazone (ACN)
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Table N: Chromatography Evaluation for Stimulants. Methods 1-9 
 
Method 1 2 3 4 5 6 7 8 9
Elution pH Low Low Low Low Low Low Low Low Low
Loading pH 3 3 3 7 7 7 10 10 10
Trap Column c8 c18 HLB c8 c18 HLB c8 c18 HLB
Elution Solvent ACN ACN ACN ACN ACN ACN ACN ACN ACN
Cocaine (H2O)
Cocaine (MeOH)
Cocaine (ACN)
Amphetamine (H2O)
Amphetamine (MeOH)
Amphetamine (ACN)
MDMA (H2O)
MDMA (MeOH)
MDMA (ACN)
Methamphetamine (H2O)
Methamphetamine (MeOH)
Methamphetamine (ACN)
Mephedrone (H2O)
Mephedrone (MeOH)
Mephedrone (ACN)
Cathinone (H2O)
Cathinone (MeOH)
Cathinone (ACN)
Butylone (H2O)
Butylone (MeOH)
Butylone (ACN)
Ephedrine (H2O)
Ephedrine (MeOH)
Ephedrine (ACN)
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Table O: Chromatography Evaluation for Stimulants. Methods 10-18 
 
Method 10 11 12 13 14 15 16 17 18
Elution pH High High High High High High High High High
Loading pH 3 3 3 7 7 7 10 10 10
Trap Column c8 c18 HLB c8 c18 HLB c8 c18 HLB
Elution Solvent ACN ACN ACN ACN ACN ACN ACN ACN ACN
Cocaine (H2O)
Cocaine (MeOH)
Cocaine (ACN)
Amphetamine (H2O)
Amphetamine (MeOH)
Amphetamine (ACN)
MDMA (H2O)
MDMA (MeOH)
MDMA (ACN)
Methamphetamine (H2O)
Methamphetamine (MeOH)
Methamphetamine (ACN)
Mephedrone (H2O)
Mephedrone (MeOH)
Mephedrone (ACN)
Cathinone (H2O)
Cathinone (MeOH)
Cathinone (ACN)
Butylone (H2O)
Butylone (MeOH)
Butylone (ACN)
Ephedrine (H2O)
Ephedrine (MeOH)
Ephedrine (ACN)
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Table P: Chromatography Evaluation for Stimulants. Methods 19-27 
 
Method 19 20 21 22 23 24 25 26 27
Elution pH Low Low Low Low Low Low Low Low Low
Loading pH 3 3 3 7 7 7 10 10 10
Trap Column c8 c18 HLB c8 c18 HLB c8 c18 HLB
Elution Solvent MeOH MeOH MeOH MeOH MeOH MeOH MeOH MeOH MeOH
Cocaine (H2O)
Cocaine (MeOH)
Cocaine (ACN)
Amphetamine (H2O)
Amphetamine (MeOH)
Amphetamine (ACN)
MDMA (H2O)
MDMA (MeOH)
MDMA (ACN)
Methamphetamine (H2O)
Methamphetamine (MeOH)
Methamphetamine (ACN)
Mephedrone (H2O)
Mephedrone (MeOH)
Mephedrone (ACN)
Cathinone (H2O)
Cathinone (MeOH)
Cathinone (ACN)
Butylone (H2O)
Butylone (MeOH)
Butylone (ACN)
Ephedrine (H2O)
Ephedrine (MeOH)
Ephedrine (ACN)
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Table Q: Chromatography Evaluation for Stimulants. Methods 28-36 
 
Method 28 29 30 31 32 33 34 35 36
Elution pH High High High High High High High High High
Loading pH 3 3 3 7 7 7 10 10 10
Trap Column c8 c18 HLB c8 c18 HLB c8 c18 HLB
Elution Solvent MeOH MeOH MeOH MeOH MeOH MeOH MeOH MeOH MeOH
Cocaine (H2O)
Cocaine (MeOH)
Cocaine (ACN)
Amphetamine (H2O)
Amphetamine (MeOH)
Amphetamine (ACN)
MDMA (H2O)
MDMA (MeOH)
MDMA (ACN)
Methamphetamine (H2O)
Methamphetamine (MeOH)
Methamphetamine (ACN)
Mephedrone (H2O)
Mephedrone (MeOH)
Mephedrone (ACN)
Cathinone (H2O)
Cathinone (MeOH)
Cathinone (ACN)
Butylone (H2O)
Butylone (MeOH)
Butylone (ACN)
Ephedrine (H2O)
Ephedrine (MeOH)
Ephedrine (ACN)
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Table R: Chromatography Evaluation for Narcotics. Methods 1-9 
 
Method 1 2 3 4 5 6 7 8 9
Elution pH Low Low Low Low Low Low Low Low Low
Loading pH 3 3 3 7 7 7 10 10 10
Trap Column c8 c18 HLB c8 c18 HLB c8 c18 HLB
Elution Solvent ACN ACN ACN ACN ACN ACN ACN ACN ACN
Codeine (H2O)
Codeine (MeOH)
Codeine (ACN)
Hydromorphone (H2O)
Hydromorphone (MeOH)
Hydromorphone (ACN)
Diamorphine (Heroin) (H2O)
Diamorphine (Heroin)  (MeOH)
Diamorphine (Heroin) (ACN)
Fentanyl (H2O)
Fentanyl (MeOH)
Fentanyl (ACN)
Methadone (H2O)
Methadone (MeOH)
Methadone (ACN)
Morphine (H2O)
Morphine (MeOH)
Morphine (ACN)
Oxycodone (H2O)
Oxycodone (MeOH)
Oxycodone (ACN)
Pethidine (H2O)
Pethidine (MeOH)
Pethidine (ACN)
Dihydrocodeine (H2O)
Dihydrocodeine (MeOH)
Dihydrocodeine (ACN)
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Table S: Chromatography Evaluation for Narcotics. Methods 10-18 
 
Method 10 11 12 13 14 15 16 17 18
Elution pH High High High High High High High High High
Loading pH 3 3 3 7 7 7 10 10 10
Trap Column c8 c18 HLB c8 c18 HLB c8 c18 HLB
Elution Solvent ACN ACN ACN ACN ACN ACN ACN ACN ACN
Codeine (H2O)
Codeine (MeOH)
Codeine (ACN)
Hydromorphone (H2O)
Hydromorphone (MeOH)
Hydromorphone (ACN)
Diamorphine (Heroin) (H2O)
Diamorphine (Heroin)  (MeOH)
Diamorphine (Heroin) (ACN)
Fentanyl (H2O)
Fentanyl (MeOH)
Fentanyl (ACN)
Methadone (H2O)
Methadone (MeOH)
Methadone (ACN)
Morphine (H2O)
Morphine (MeOH)
Morphine (ACN)
Oxycodone (H2O)
Oxycodone (MeOH)
Oxycodone (ACN)
Pethidine (H2O)
Pethidine (MeOH)
Pethidine (ACN)
Dihydrocodeine (H2O)
Dihydrocodeine (MeOH)
Dihydrocodeine (ACN)
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Table T: Chromatography Evaluation for Narcotics. Methods 19-27 
 
Method 19 20 21 22 23 24 25 26 27
Elution pH Low Low Low Low Low Low Low Low Low
Loading pH 3 3 3 7 7 7 10 10 10
Trap Column c8 c18 HLB c8 c18 HLB c8 c18 HLB
Elution Solvent MeOH MeOH MeOH MeOH MeOH MeOH MeOH MeOH MeOH
Codeine (H2O)
Codeine (MeOH)
Codeine (ACN)
Hydromorphone (H2O)
Hydromorphone (MeOH)
Hydromorphone (ACN)
Diamorphine (Heroin) (H2O)
Diamorphine (Heroin)  (MeOH)
Diamorphine (Heroin) (ACN)
Fentanyl (H2O)
Fentanyl (MeOH)
Fentanyl (ACN)
Methadone (H2O)
Methadone (MeOH)
Methadone (ACN)
Morphine (H2O)
Morphine (MeOH)
Morphine (ACN)
Oxycodone (H2O)
Oxycodone (MeOH)
Oxycodone (ACN)
Pethidine (H2O)
Pethidine (MeOH)
Pethidine (ACN)
Dihydrocodeine (H2O)
Dihydrocodeine (MeOH)
Dihydrocodeine (ACN)
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Table U: Chromatography Evaluation for Narcotics. Methods 28-36 
 
Method 28 29 30 31 32 33 34 35 36
Elution pH High High High High High High High High High
Loading pH 3 3 3 7 7 7 10 10 10
Trap Column c8 c18 HLB c8 c18 HLB c8 c18 HLB
Elution Solvent MeOH MeOH MeOH MeOH MeOH MeOH MeOH MeOH MeOH
Codeine (H2O)
Codeine (MeOH)
Codeine (ACN)
Hydromorphone (H2O)
Hydromorphone (MeOH)
Hydromorphone (ACN)
Diamorphine (Heroin) (H2O)
Diamorphine (Heroin)  (MeOH)
Diamorphine (Heroin) (ACN)
Fentanyl (H2O)
Fentanyl (MeOH)
Fentanyl (ACN)
Methadone (H2O)
Methadone (MeOH)
Methadone (ACN)
Morphine (H2O)
Morphine (MeOH)
Morphine (ACN)
Oxycodone (H2O)
Oxycodone (MeOH)
Oxycodone (ACN)
Pethidine (H2O)
Pethidine (MeOH)
Pethidine (ACN)
Dihydrocodeine (H2O)
Dihydrocodeine (MeOH)
Dihydrocodeine (ACN)
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Table V: Chromatography Evaluation for Beta Blockers. Methods 1-9 
 
Compound 1 2 3 4 5 6 7 8 9
Elution pH Low Low Low Low Low Low Low Low Low
Loading pH 3 3 3 7 7 7 10 10 10
Trap Column c8 c18 HLB c8 c18 HLB c8 c18 HLB
Elution Solvent ACN ACN ACN ACN ACN ACN ACN ACN ACN
Metoprolol (H2O)
Metoprolol (MeOH)
Metoprolol (ACN)
Propranolol (H2O)
Propranolol (MeOH)
Propranolol (ACN)
Atenolol (H2O)
Atenolol (MeOH)
Atenolol (ACN)
Betaxolol (H2O)
Betaxolol (MeOH)
Betaxolol (ACN)
Timolol (H2O)
Timolol (MeOH)
Timolol (ACN)
Carvedilol (H2O)
Carvedilol (MeOH)
Carvedilol (ACN)
Esmolol (H2O)
Esmolol (MeOH)
Esmolol (ACN)
Labetalol (H2O)
Labetalol (MeOH)
Labetalol (ACN)
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Table W: Chromatography Evaluation for Beta Blockers. Methods 10-18 
 
Compound 10 11 12 13 14 15 16 17 18
Elution pH High High High High High High High High High
Loading pH 3 3 3 7 7 7 10 10 10
Trap Column c8 c18 HLB c8 c18 HLB c8 c18 HLB
Elution Solvent ACN ACN ACN ACN ACN ACN ACN ACN ACN
Metoprolol (H2O)
Metoprolol (MeOH)
Metoprolol (ACN)
Propranolol (H2O)
Propranolol (MeOH)
Propranolol (ACN)
Atenolol (H2O)
Atenolol (MeOH)
Atenolol (ACN)
Betaxolol (H2O)
Betaxolol (MeOH)
Betaxolol (ACN)
Timolol (H2O)
Timolol (MeOH)
Timolol (ACN)
Carvedilol (H2O)
Carvedilol (MeOH)
Carvedilol (ACN)
Esmolol (H2O)
Esmolol (MeOH)
Esmolol (ACN)
Labetalol (H2O)
Labetalol (MeOH)
Labetalol (ACN)
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Table X: Chromatography Evaluation for Beta Blockers. Methods 19-27 
 
Compound 19 20 21 22 23 24 25 26 27
Elution pH Low Low Low Low Low Low Low Low Low
Loading pH 3 3 3 7 7 7 10 10 10
Trap Column c8 c18 HLB c8 c18 HLB c8 c18 HLB
Elution Solvent MeOH MeOH MeOH MeOH MeOH MeOH MeOH MeOH MeOH
Metoprolol (H2O)
Metoprolol (MeOH)
Metoprolol (ACN)
Propranolol (H2O)
Propranolol (MeOH)
Propranolol (ACN)
Atenolol (H2O)
Atenolol (MeOH)
Atenolol (ACN)
Betaxolol (H2O)
Betaxolol (MeOH)
Betaxolol (ACN)
Timolol (H2O)
Timolol (MeOH)
Timolol (ACN)
Carvedilol (H2O)
Carvedilol (MeOH)
Carvedilol (ACN)
Esmolol (H2O)
Esmolol (MeOH)
Esmolol (ACN)
Labetalol (H2O)
Labetalol (MeOH)
Labetalol (ACN)
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Table Y: Chromatography Evaluation for Beta Blockers. Methods 28-36 
 
Compound 28 29 30 31 32 33 34 35 36
Elution pH High High High High High High High High High
Loading pH 3 3 3 7 7 7 10 10 10
Trap Column c8 c18 HLB c8 c18 HLB c8 c18 HLB
Elution Solvent MeOH MeOH MeOH MeOH MeOH MeOH MeOH MeOH MeOH
Metoprolol (H2O)
Metoprolol (MeOH)
Metoprolol (ACN)
Propranolol (H2O)
Propranolol (MeOH)
Propranolol (ACN)
Atenolol (H2O)
Atenolol (MeOH)
Atenolol (ACN)
Betaxolol (H2O)
Betaxolol (MeOH)
Betaxolol (ACN)
Timolol (H2O)
Timolol (MeOH)
Timolol (ACN)
Carvedilol (H2O)
Carvedilol (MeOH)
Carvedilol (ACN)
Esmolol (H2O)
Esmolol (MeOH)
Esmolol (ACN)
Labetalol (H2O)
Labetalol (MeOH)
Labetalol (ACN)
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Table Z: Chromatography Evaluation for Phenethylamines. Methods 1-9 
 
Method 1 2 3 4 5 6 7 8 9
Elution pH Low Low Low Low Low Low Low Low Low
Loading pH 3 3 3 7 7 7 10 10 10
Trap Column c8 c18 HLB c8 c18 HLB c8 c18 HLB
Elution Solvent ACN ACN ACN ACN ACN ACN ACN ACN ACN
25I-NBOMe (H2O)
25I-NBOMe (MeOH)
25I-NBOMe (ACN)
25C-NBOMe (H2O)
25C-NBOMe (MeOH)
25C-NBOMe (ACN)
Phentermine (H2O)
Phentermine (MeOH)
Phentermine (ACN)
Mescaline (H2O)
Mescaline (MeOH)
Mescaline (ACN)
5-APB (H2O)
5-APB (MeOH)
5-APB (ACN)
2C-B (H2O)
2C-B (MeOH)
2C-B (ACN)
2C-H (H2O)
2C-H (MeOH)
2C-H (ACN)
2C-I (H2O)
2C-I (MeOH)
2C-I (ACN)
25N-NBOMe (H2O)
25N-NBOMe (MeOH)
25N-NBOMe (ACN)
25D-NBOMe (H2O)
25D-NBOMe (MeOH)
25D-NBOMe (ACN)
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Table AA: Chromatography Evaluation for Phenethylamine Compounds. Methods 10-18 
 
 
Method 10 11 12 13 14 15 16 17 18
Elution pH High High High High High High High High High
Loading pH 3 3 3 7 7 7 10 10 10
Trap Column c8 c18 HLB c8 c18 HLB c8 c18 HLB
Elution Solvent ACN ACN ACN ACN ACN ACN ACN ACN ACN
25I-NBOMe (H2O)
25I-NBOMe (MeOH)
25I-NBOMe (ACN)
25C-NBOMe (H2O)
25C-NBOMe (MeOH)
25C-NBOMe (ACN)
Phentermine (H2O)
Phentermine (MeOH)
Phentermine (ACN)
Mescaline (H2O)
Mescaline (MeOH)
Mescaline (ACN)
5-APB (H2O)
5-APB (MeOH)
5-APB (ACN)
2C-B (H2O)
2C-B (MeOH)
2C-B (ACN)
2C-H (H2O)
2C-H (MeOH)
2C-H (ACN)
2C-I (H2O)
2C-I (MeOH)
2C-I (ACN)
25N-NBOMe (H2O)
25N-NBOMe (MeOH)
25N-NBOMe (ACN)
25D-NBOMe (H2O)
25D-NBOMe (MeOH)
25D-NBOMe (ACN)
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Table AB: Chromatography Evaluation of Phenethylamines. Methods 19-27.  
 
Method 19 20 21 22 23 24 25 26 27
Elution pH Low Low Low Low Low Low Low Low Low
Loading pH 3 3 3 7 7 7 10 10 10
Trap Column c8 c18 HLB c8 c18 HLB c8 c18 HLB
Elution Solvent MeOH MeOH MeOH MeOH MeOH MeOH MeOH MeOH MeOH
25I-NBOMe (H2O)
25I-NBOMe (MeOH)
25I-NBOMe (ACN)
25C-NBOMe (H2O)
25C-NBOMe (MeOH)
25C-NBOMe (ACN)
Phentermine (H2O)
Phentermine (MeOH)
Phentermine (ACN)
Mescaline (H2O)
Mescaline (MeOH)
Mescaline (ACN)
5-APB (H2O)
5-APB (MeOH)
5-APB (ACN)
2C-B (H2O)
2C-B (MeOH)
2C-B (ACN)
2C-H (H2O)
2C-H (MeOH)
2C-H (ACN)
2C-I (H2O)
2C-I (MeOH)
2C-I (ACN)
25N-NBOMe (H2O)
25N-NBOMe (MeOH)
25N-NBOMe (ACN)
25D-NBOMe (H2O)
25D-NBOMe (MeOH)
25D-NBOMe (ACN)
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Table AC: Chromatography Evaluation of Phenethylamines. Methods 28-36 
 
Method 28 29 30 31 32 33 34 35 36
Elution pH High High High High High High High High High
Loading pH 3 3 3 7 7 7 10 10 10
Trap Column c8 c18 HLB c8 c18 HLB c8 c18 HLB
Elution Solvent MeOH MeOH MeOH MeOH MeOH MeOH MeOH MeOH MeOH
25I-NBOMe (H2O)
25I-NBOMe (MeOH)
25I-NBOMe (ACN)
25C-NBOMe (H2O)
25C-NBOMe (MeOH)
25C-NBOMe (ACN)
Phentermine (H2O)
Phentermine (MeOH)
Phentermine (ACN)
Mescaline (H2O)
Mescaline (MeOH)
Mescaline (ACN)
5-APB (H2O)
5-APB (MeOH)
5-APB (ACN)
2C-B (H2O)
2C-B (MeOH)
2C-B (ACN)
2C-H (H2O)
2C-H (MeOH)
2C-H (ACN)
2C-I (H2O)
2C-I (MeOH)
2C-I (ACN)
25N-NBOMe (H2O)
25N-NBOMe (MeOH)
25N-NBOMe (ACN)
25D-NBOMe (H2O)
25D-NBOMe (MeOH)
25D-NBOMe (ACN)
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Table AD: Chromatography Evaluation of Benzodiazepines. Methods 1-9. 
 
Method 1 2 3 4 5 6 7 8 9
Elution pH Low Low Low Low Low Low Low Low Low
Loading pH 3 3 3 7 7 7 10 10 10
Trap Column c8 c18 HLB c8 c18 HLB c8 c18 HLB
Elution Solvent ACN ACN ACN ACN ACN ACN ACN ACN ACN
Alprazolam (Water)
Alprazolam (MeOH)
Alprazolam (ACN)
Clonazepam (Water)
Clonazepam (MeOH)
Clonazepam (ACN)
Flunitrazepam (Water)
Flunitrazepam (MeOH)
Flunitrazepam (ACN)
Triazolam (Water)
Triazolam (MeOH)
Triazolam (ACN)
Oxazepam (Water)
Oxazepam (MeOH)
Oxazepam (ACN)
Nordiazepam (Water)
Nordiazepam (MeOH)
Nordiazepam (ACN)
Temazepam (Water)
Temazepam (MeOH)
Temazepam (ACN)
Bromazepam (Water)
Bromazepam (MeOH)
Bromazepam (ACN)
Chlordiazepoxide (Water)
Chlordiazepoxide (MeOH)
Chlordiazepoxide (ACN)
Clobazam (Water)
Clobazam (MeOH)
Clobazam (ACN)
Diazepam (Water)
Diazepam (MeOH)
Diazepam (ACN)
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Table AE: Chromatography Evaluation for Benzodiazepines. Methods 10-18. 
 
Method 10 11 12 13 14 15 16 17 18
Elution pH High High High High High High High High High
Loading pH 3 3 3 7 7 7 10 10 10
Trap Column c8 c18 HLB c8 c18 HLB c8 c18 HLB
Elution Solvent ACN ACN ACN ACN ACN ACN ACN ACN ACN
Alprazolam (Water)
Alprazolam (MeOH)
Alprazolam (ACN)
Clonazepam (Water)
Clonazepam (MeOH)
Clonazepam (ACN)
Flunitrazepam (Water)
Flunitrazepam (MeOH)
Flunitrazepam (ACN)
Triazolam (Water)
Triazolam (MeOH)
Triazolam (ACN)
Oxazepam (Water)
Oxazepam (MeOH)
Oxazepam (ACN)
Nordiazepam (Water)
Nordiazepam (MeOH)
Nordiazepam (ACN)
Temazepam (Water)
Temazepam (MeOH)
Temazepam (ACN)
Bromazepam (Water)
Bromazepam (MeOH)
Bromazepam (ACN)
Chlordiazepoxide (Water)
Chlordiazepoxide (MeOH)
Chlordiazepoxide (ACN)
Clobazam (Water)
Clobazam (MeOH)
Clobazam (ACN)
Diazepam (Water)
Diazepam (MeOH)
Diazepam (ACN)
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Table AF: Chromatography Evaluation for Benzodiazepines. Methods 19-27 
 
Method 19 20 21 22 23 24 25 26 27
Elution pH Low Low Low Low Low Low Low Low Low
Loading pH 3 3 3 7 7 7 10 10 10
Trap Column c8 c18 HLB c8 c18 HLB c8 c18 HLB
Elution Solvent MeOH MeOH MeOH MeOH MeOH MeOH MeOH MeOH MeOH
Alprazolam (Water)
Alprazolam (MeOH)
Alprazolam (ACN)
Clonazepam (Water)
Clonazepam (MeOH)
Clonazepam (ACN)
Flunitrazepam (Water)
Flunitrazepam (MeOH)
Flunitrazepam (ACN)
Triazolam (Water)
Triazolam (MeOH)
Triazolam (ACN)
Oxazepam (Water)
Oxazepam (MeOH)
Oxazepam (ACN)
Nordiazepam (Water)
Nordiazepam (MeOH)
Nordiazepam (ACN)
Temazepam (Water)
Temazepam (MeOH)
Temazepam (ACN)
Bromazepam (Water)
Bromazepam (MeOH)
Bromazepam (ACN)
Chlordiazepoxide (Water)
Chlordiazepoxide (MeOH)
Chlordiazepoxide (ACN)
Clobazam (Water)
Clobazam (MeOH)
Clobazam (ACN)
Diazepam (Water)
Diazepam (MeOH)
Diazepam (ACN)
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Table AG: Chromatography Evaluation of Benzodiazepines. Methods 28-36 
 
Method 28 29 30 31 32 33 34 35 36
Elution pH High High High High High High High High High
Loading pH 3 3 3 7 7 7 10 10 10
Trap Column c8 c18 HLB c8 c18 HLB c8 c18 HLB
Elution Solvent MeOH MeOH MeOH MeOH MeOH MeOH MeOH MeOH MeOH
Alprazolam (Water)
Alprazolam (MeOH)
Alprazolam (ACN)
Clonazepam (Water)
Clonazepam (MeOH)
Clonazepam (ACN)
Flunitrazepam (Water)
Flunitrazepam (MeOH)
Flunitrazepam (ACN)
Triazolam (Water)
Triazolam (MeOH)
Triazolam (ACN)
Oxazepam (Water)
Oxazepam (MeOH)
Oxazepam (ACN)
Nordiazepam (Water)
Nordiazepam (MeOH)
Nordiazepam (ACN)
Temazepam (Water)
Temazepam (MeOH)
Temazepam (ACN)
Bromazepam (Water)
Bromazepam (MeOH)
Bromazepam (ACN)
Chlordiazepoxide (Water)
Chlordiazepoxide (MeOH)
Chlordiazepoxide (ACN)
Clobazam (Water)
Clobazam (MeOH)
Clobazam (ACN)
Diazepam (Water)
Diazepam (MeOH)
Diazepam (ACN)
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Table AH: Chromatography Evaluation of Piperazines. Methods 1-9. 
 
Method 1 2 3 4 5 6 7 8 9
Elution pH Low Low Low Low Low Low Low Low Low
Loading pH 3 3 3 7 7 7 10 10 10
Trap Column c8 c18 HLB c8 c18 HLB c8 c18 HLB
Elution Solvent ACN ACN ACN ACN ACN ACN ACN ACN ACN
1-Benzylpiperazine (BZP) (Water)
1-Benzylpiperazine (BZP) (MeOH)
1-Benzylpiperazine (BZP) (ACN)
2,3-Dichlorophenylpiperazine (DCPP) (Water)
2,3-Dichlorophenylpiperazine (DCPP) (MeOH)
2,3-Dichlorophenylpiperazine (DCPP) (ACN)
1,4-Dibenzylpiperazine (DBZP) (Water)
1,4-Dibenzylpiperazine (DBZP) (MeOH)
1,4-Dibenzylpiperazine (DBZP) (ACN)
4-Methyl-1-benzylpiperazine (MBZP) (Water)
4-Methyl-1-benzylpiperazine (MBZP) (MeOH)
4-Methyl-1-benzylpiperazine (MBZP) (ACN)
3-Chlorophenylpiperazine (mCPP) (Water)
3-Chlorophenylpiperazine (mCPP) (MeOH)
3-Chlorophenylpiperazine (mCPP) (ACN)
4-Methoxyphenylpiperazine (MeOPP) (Water)
4-Methoxyphenylpiperazine (MeOPP) (MeOH)
4-Methoxyphenylpiperazine (MeOPP) (ACN)
4-Chlorophenylpiperazine (pCPP) (Water)
4-Chlorophenylpiperazine (pCPP) (MeOH)
4-Chlorophenylpiperazine (pCPP) (ACN)
4-Fluorophenylpiperazine (pFPP) (Water)
4-Fluorophenylpiperazine (pFPP) (MeOH)
4-Fluorophenylpiperazine (pFPP) (ACN)
3-Trifluoromethylphenylpiperazine (TFMPP) (Water)
3-Trifluoromethylphenylpiperazine (TFMPP) (MeOH)
3-Trifluoromethylphenylpiperazine (TFMPP) (ACN)
4-fluoro BZP (Water)
4-fluoro BZP (MeOH)
4-fluoro BZP (ACN)
Phenyl Piperazine (Water)
Phenyl Piperazine (MeOH)
Phenyl Piperazine (ACN)
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Table AI: Chromatography Evaluation of Piperazines. Methods 10-18. 
 
Method 10 11 12 13 14 15 16 17 18
Elution pH High High High High High High High High High
Loading pH 3 3 3 7 7 7 10 10 10
Trap Column c8 c18 HLB c8 c18 HLB c8 c18 HLB
Elution Solvent ACN ACN ACN ACN ACN ACN ACN ACN ACN
1-Benzylpiperazine (BZP) (Water)
1-Benzylpiperazine (BZP) (MeOH)
1-Benzylpiperazine (BZP) (ACN)
2,3-Dichlorophenylpiperazine (DCPP) (Water)
2,3-Dichlorophenylpiperazine (DCPP) (MeOH)
2,3-Dichlorophenylpiperazine (DCPP) (ACN)
1,4-Dibenzylpiperazine (DBZP) (Water)
1,4-Dibenzylpiperazine (DBZP) (MeOH)
1,4-Dibenzylpiperazine (DBZP) (ACN)
4-Methyl-1-benzylpiperazine (MBZP) (Water)
4-Methyl-1-benzylpiperazine (MBZP) (MeOH)
4-Methyl-1-benzylpiperazine (MBZP) (ACN)
3-Chlorophenylpiperazine (mCPP) (Water)
3-Chlorophenylpiperazine (mCPP) (MeOH)
3-Chlorophenylpiperazine (mCPP) (ACN)
4-Methoxyphenylpiperazine (MeOPP) (Water)
4-Methoxyphenylpiperazine (MeOPP) (MeOH)
4-Methoxyphenylpiperazine (MeOPP) (ACN)
4-Chlorophenylpiperazine (pCPP) (Water)
4-Chlorophenylpiperazine (pCPP) (MeOH)
4-Chlorophenylpiperazine (pCPP) (ACN)
4-Fluorophenylpiperazine (pFPP) (Water)
4-Fluorophenylpiperazine (pFPP) (MeOH)
4-Fluorophenylpiperazine (pFPP) (ACN)
3-Trifluoromethylphenylpiperazine (TFMPP) (Water)
3-Trifluoromethylphenylpiperazine (TFMPP) (MeOH)
3-Trifluoromethylphenylpiperazine (TFMPP) (ACN)
4-fluoro BZP (Water)
4-fluoro BZP (MeOH)
4-fluoro BZP (ACN)
Phenyl Piperazine (Water)
Phenyl Piperazine (MeOH)
Phenyl Piperazine (ACN)
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Table AJ: Chromatography Evaluation of Piperazines. Methods 19-27  
 
Method 19 20 21 22 23 24 25 26 27
Elution pH Low Low Low Low Low Low Low Low Low
Loading pH 3 3 3 7 7 7 10 10 10
Trap Column c8 c18 HLB c8 c18 HLB c8 c18 HLB
Elution Solvent MeOH MeOH MeOH MeOH MeOH MeOH MeOH MeOH MeOH
1-Benzylpiperazine (BZP) (Water)
1-Benzylpiperazine (BZP) (MeOH)
1-Benzylpiperazine (BZP) (ACN)
2,3-Dichlorophenylpiperazine (DCPP) (Water)
2,3-Dichlorophenylpiperazine (DCPP) (MeOH)
2,3-Dichlorophenylpiperazine (DCPP) (ACN)
1,4-Dibenzylpiperazine (DBZP) (Water)
1,4-Dibenzylpiperazine (DBZP) (MeOH)
1,4-Dibenzylpiperazine (DBZP) (ACN)
4-Methyl-1-benzylpiperazine (MBZP) (Water)
4-Methyl-1-benzylpiperazine (MBZP) (MeOH)
4-Methyl-1-benzylpiperazine (MBZP) (ACN)
3-Chlorophenylpiperazine (mCPP) (Water)
3-Chlorophenylpiperazine (mCPP) (MeOH)
3-Chlorophenylpiperazine (mCPP) (ACN)
4-Methoxyphenylpiperazine (MeOPP) (Water)
4-Methoxyphenylpiperazine (MeOPP) (MeOH)
4-Methoxyphenylpiperazine (MeOPP) (ACN)
4-Chlorophenylpiperazine (pCPP) (Water)
4-Chlorophenylpiperazine (pCPP) (MeOH)
4-Chlorophenylpiperazine (pCPP) (ACN)
4-Fluorophenylpiperazine (pFPP) (Water)
4-Fluorophenylpiperazine (pFPP) (MeOH)
4-Fluorophenylpiperazine (pFPP) (ACN)
3-Trifluoromethylphenylpiperazine (TFMPP) (Water)
3-Trifluoromethylphenylpiperazine (TFMPP) (MeOH)
3-Trifluoromethylphenylpiperazine (TFMPP) (ACN)
4-fluoro BZP (Water)
4-fluoro BZP (MeOH)
4-fluoro BZP (ACN)
Phenyl Piperazine (Water)
Phenyl Piperazine (MeOH)
Phenyl Piperazine (ACN)
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Table AK: Chromatography Evaluation of Piperazines. Methods 28-36. 
 
  
Method 28 29 30 31 32 33 34 35 36
Elution pH High High High High High High High High High
Loading pH 3 3 3 7 7 7 10 10 10
Trap Column c8 c18 HLB c8 c18 HLB c8 c18 HLB
Elution Solvent MeOH MeOH MeOH MeOH MeOH MeOH MeOH MeOH MeOH
1-Benzylpiperazine (BZP) (Water)
1-Benzylpiperazine (BZP) (MeOH)
1-Benzylpiperazine (BZP) (ACN)
2,3-Dichlorophenylpiperazine (DCPP) (Water)
2,3-Dichlorophenylpiperazine (DCPP) (MeOH)
2,3-Dichlorophenylpiperazine (DCPP) (ACN)
1,4-Dibenzylpiperazine (DBZP) (Water)
1,4-Dibenzylpiperazine (DBZP) (MeOH)
1,4-Dibenzylpiperazine (DBZP) (ACN)
4-Methyl-1-benzylpiperazine (MBZP) (Water)
4-Methyl-1-benzylpiperazine (MBZP) (MeOH)
4-Methyl-1-benzylpiperazine (MBZP) (ACN)
3-Chlorophenylpiperazine (mCPP) (Water)
3-Chlorophenylpiperazine (mCPP) (MeOH)
3-Chlorophenylpiperazine (mCPP) (ACN)
4-Methoxyphenylpiperazine (MeOPP) (Water)
4-Methoxyphenylpiperazine (MeOPP) (MeOH)
4-Methoxyphenylpiperazine (MeOPP) (ACN)
4-Chlorophenylpiperazine (pCPP) (Water)
4-Chlorophenylpiperazine (pCPP) (MeOH)
4-Chlorophenylpiperazine (pCPP) (ACN)
4-Fluorophenylpiperazine (pFPP) (Water)
4-Fluorophenylpiperazine (pFPP) (MeOH)
4-Fluorophenylpiperazine (pFPP) (ACN)
3-Trifluoromethylphenylpiperazine (TFMPP) (Water)
3-Trifluoromethylphenylpiperazine (TFMPP) (MeOH)
3-Trifluoromethylphenylpiperazine (TFMPP) (ACN)
4-fluoro BZP (Water)
4-fluoro BZP (MeOH)
4-fluoro BZP (ACN)
Phenyl Piperazine (Water)
Phenyl Piperazine (MeOH)
Phenyl Piperazine (ACN)
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